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ABSTRACT 
 
Pneumocystis pneumonia (PCP) is one of the most prevalent diseases in HIV-positive and 
other immunosuppressed patients. It is caused by the opportunistic fungal pathogen 
Pneumocystis jirovecii. Dihydropteroate synthase (DHPS) mutations in P. jirovecii have 
been linked to resistance to trimethoprim-sulphamethoxazole (cotrimoxazole), the main 
treatment and prophylaxis used for PCP. DHPS mutations have been identified globally, 
predominantly in developed countries. This study investigated the P. jirovecii DHPS 
genotypes in PCP-positive patients from Chris Hani Baragwanath Hospital in Gauteng 
Province, South Africa.  
 
During the period March 2005 through June 2009, 266 patients were enrolled in the study 
and 306 specimens were collected. P. jirovecii was identified in 67% (205/306) of these 
specimens with quantitative real-time PCR (qPCR). The qPCR had a sensitivity of 98% 
and a specificity of 70%, compared with the immunofluorescence assay (IFA). Using 
sequencing and cloning techniques, 64% (110/173) of the nested PCR-positive specimens 
contained P. jirovecii with mutant DHPS genotypes. There was no association between 
patients harbouring P. jirovecii with mutant DHPS genotypes and in-hospital patient 
outcome (p-value = 0.19). As part of this project the Roche MagNA Pure Compact 
(RMPC) instrument and technology was validated for use as a new DNA extraction 
method. The RMPC was quick and easy to use compared to the Qiagen manual extraction 
method.  
 
The specificity of the qPCR was compromised by the high number of apparent false 
positive results obtained by the assay. However, as the IFA is an imperfect gold standard, 
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these are probably true cases of infection or colonisation. This study found a higher 
proportion of P. jirovecii with DHPS mutant genotypes than wild type in PCP patients, 
which is unusual. The most probable reason for this is the widespread use of sulfa drugs, 
which are thought to select for these mutations. While this study did not find an association 
between DHPS mutations and adverse patient outcome, there have been contradictory 
findings. If further investigations reveal that DHPS mutations affect patient treatment or 
outcome, it will have major implications for the management of PCP in the country. 
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CHAPTER 1 - INTRODUCTION 
 
1.1 Pneumocystis jirovecii 
1.1.1 History  
In 1909, Pneumocystis was first identified by Charlos Chagas in Brazil. He was examining 
the lungs of guinea pigs that were inoculated with trypanosome-positive blood. He 
believed that he was looking at a new life stage of the protozoan flagellate Trypanosoma 
cruzi and therefore suggested the name of Schizotrypanum. Antonio Carini, in 1910, found 
the same organism in rat lungs also infected with trypanosomes and thought that it was a 
new type of trypanosome. In 1912, P. Delanoë and M. Delanoë found the same organisms 
in the lungs of sewer rats uninfected with trypanosomes and concluded that this was a 
different species and they proposed the name Pneumocystis carinii [1-4]. 
 
For many years after it was discovered, it was believed that P. carinii was a protozoan 
because it displayed morphological features typical of protozoa and because it responded 
to anti-protozoan treatment. However, in the 1970s, there were suggestions that P. carinii 
may be a fungus. This was confirmed in 1988, after sequencing of the small ribosomal 
RNA subunit [1;2;4;5]. 
 
Further study showed that there were different forms of Pneumocystis specific for different 
hosts [2]. Pneumocystis has been found in humans, rats, mice, pigs and horses, amongst 
others. A trinomial naming system was used to differentiate the species, e.g. Pneumocystis 
carinii f. sp. carinii referred to the species of Pneumocystis that infected rats and 
Pneumocystis carinii f. sp. hominis referred to the species that infected humans [6]. As 
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sufficient taxonomic information became available, nomenclature was revised. The form 
that infects humans was named Pneumocystis jirovecii after Otto Jirovec, a pathologist 
who initially reported Pneumocystis in humans, and the form that infects rats was named 
P. carinii [2;6]. PCP was originally the abbreviation for Pneumocystis carinii pneumonia. 
After the organism’s name was changed to P. jirovecii, the abbreviation was kept and 
subsequently stands for Pneumocystis pneumonia. 
 
1.1.2 Classification 
Pneumocystis species are currently classified in the Phylum Ascomycota, Subphylum 
Taphrinomycotina, Class Pneumocystidomycetes, Order Pneumocystidales, and Family 
Pneumocystidaceae [2;7].  
 
1.1.3 Morphology and life cycle 
To date, Pneumocystis organisms have not been successfully cultured, which is the core 
reason why so much remains unknown about the morphology and life cycle of the 
organism [8;9]. Nonetheless, hypothesised life cycles have been established and are 
periodically revised, based largely on microscopic observations. The two main stages of 
the organism that were identified initially, were the trophozoite stage measuring 2 - 5 µm 
(Figure 1.1) and the cyst stage measuring 6 - 7 µm (Figure 1.2) [2;9]. This partially 
explains why Pneumocystis was initially believed to be a parasite, as these are the two 
typical life stages of protozoan parasites.  
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Figure 1.1 Schematic diagram of the trophozoite form of P. jirovecii [9] 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic diagram of the cyst form of P. jirovecii [9] 
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According to one of the most recent proposed life cycles, Pneumocystis is thought to 
involve three main stages, namely the trophozoite, the sporocyte and the cyst [10]. The 
trophozoite stage conjugates to form a sporocyte, which undergoes meiosis and then 
mitosis to give rise to the cyst form. The cyst form contains eight spores which, when fully 
developed, are released as eight trophic forms (Figure 1.3). 
 
 
A hypothetical Pneumocystis life cycle illustrated by transmission electron micrographs and corresponding 
interpretation drawings of organisms developing in mammalian lungs. Mononuclear thin-walled trophic 
forms (small arrows) are attached to type 1 epithelial alveolar cell that is close to a capillary vessel (star). 
Following conjugation, trophic forms would evolve into thin-walled round early sporocyte. While electron-
lucent layer (arrowhead) develops in intermediate sporocytes, meiotic nuclear division proceeds. An 
additional mitotic replication leads to a thick-walled late sporocyte (arrowhead) containing eight nuclei. In 
the mature cyst, the eight spores are fully delineated. These forms are able to leave the cyst and subsequently 
attach to type I alveolar cells. A: alveolar space; CC: condensed chromosomes and spindle microtubules; N: 
nucleus; Mi: mitochondrion; V: vacuole. Arrowheads indicate thick cell wall. 
 
Figure 1.3 Proposed Pneumocystis life cycle. Adapted from Aliouat-Denis et al. [4] 
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1.1.4 Infection and transmission 
While the exact transmission route of Pneumocystis is still largely unknown, there are two 
key theories. The first is that PCP infection arises from the reactivation of a latent infection 
and the second is that PCP infection is a result of a new exposure or recent transmission.  
 
As most healthy children are seropositive in the first few years of life [11-13] and 
P. jirovecii is a known opportunistic pathogen that causes infection in people who are 
immunosuppressed, it is believed by some that this is due to the reactivation of a latent 
infection [14]. However, this theory has been challenged by the fact that Pneumocystis 
organisms have not been found in many immunocompetent people on follow-up, which 
suggests that the organism does not persist long after infection and produces a rather 
transient carrier state [15;16].  
 
The other possibility, namely that patients who are immunosuppressed acquire a new 
infection of Pneumocystis appears to be gaining support. The source of this infection is not 
indisputably known. The reservoir for the organism could be healthy or ill individuals 
colonised with the fungus (i.e. carriers), patients with current PCP infection or even the 
environment [11;15;17]. The possible routes of transmission include person-to-person and 
airborne. 
 
Healthy individuals have been shown to harbour the organism without infection [16;18-
20]. These findings prove that asymptomatic infection or colonisation occurs. Colonisation 
has been defined as the isolation of P. jirovecii DNA in respiratory samples from patients 
who show no signs and symptoms of PCP. Colonisation is not known to lead to PCP 
[18;19].  In the USA, a large proportion (22/32, 69%) of HIV-positive patients without 
Introduction 
 6 
PCP, were found to be colonised with P. jirovecii [21]. In contrast, a very low prevalence 
(0.3%, 1/384) of colonisation was found in Tanzania among HIV-positive and negative 
patients suspected of having TB. However, investigators used oral-wash specimens, which 
is not an optimal specimen type [22]. Colonised people may also play a large role in the 
transmission of PCP. 
 
Air samples from hospitals have been tested and found to contain P. jirovecii DNA, 
supporting the theory of airborne transmission [23;24]. This leads to the strong possibility 
of nosocomial spread of the organism and has lead to suggestions that PCP patients should 
be isolated from immunosuppressed patients [20;23;25-29]. An animal study exposed rats 
to sterile and unsterile surroundings, food, water, as well as PCP-infected food. Only the 
immunosuppressed rats housed in an unsterile environment acquired PCP; therefore it was 
concluded that airborne transmission was very likely [30].  
 
Many studies have suggested that person-to-person spread is the most probable route of 
transmission [20;29]. Outbreaks of PCP among transplant patients support this theory 
[27;31]. On the contrary, it has been suggested that person-to-person transmission and 
transmission from PCP patients to susceptible hosts may occur but may not be the main 
route of transmission [32;33].  
 
Most of the recent studies agree with the recent transmission theory rather than the 
reactivation of a latent infection theory [34;35]. It is suggested by some researchers that 
infection arises from recent transmission, because their results show that P. jirovecii 
dihydropteroate synthase (DHPS) mutations change over time [35;36]. These authors state 
that if reactivation of a latent infection were occurring then the genotypes would remain 
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the same. To dispute this, Nahimana et al. [14] suggested that reactivation may occur and 
that the DHPS mutations may be selected for within the patients, under the pressure of the 
sulfa drugs. Investigations on the genotypes of P. jirovecii in association with place of 
birth versus place of diagnosis were done. Allelic variation patterns in P. jirovecii were not 
associated with patients’ place of birth, but rather with place of diagnosis [37]. This finding 
strengthens the argument that patients acquire new infections.  
 
1.2 Pneumocystis pneumonia (PCP) 
Pneumocystis pneumonia is one of the most prevalent diseases in HIV-positive patients 
[2;18] but also affects certain non-HIV-infected groups. These are mainly patients on 
immunosuppressant medications such as glucocorticosteroids [2;14;38]. Mortality rates for 
PCP patients in developed countries range from 7% to 21% [39-41]. In-hospital mortality 
in children was found to be between 39% and 47% in South Africa (SA) [42;43]. PCP 
incidence may be affected by seasonality and climatic factors, particularly mean 
temperature [44-46]. 
 
1.2.1 Clinical manifestations 
The signs and symptoms of PCP in immunocompromised patients are very much the same 
as those for other atypical pneumonias [3]. The main symptoms of PCP are a dry, non-
productive cough and shortness of breath [3;47-49]. Fever and hypoxia are also common in 
PCP patients [48;50-52]. Patients presenting with the symptoms listed above should be 
further examined or tested to determine if they may have PCP.  
 
Introduction 
 8 
Symptoms in HIV-infected patients are usually seen for longer periods of time but are 
milder compared to HIV uninfected patients, despite the higher fungal loads present in 
HIV-patients [48;53-55]. In addition the mortality rate is higher in non-HIV patients 
[48;55;56]. 
 
1.2.2 Diagnosis 
PCP is a difficult disease to diagnose due to its non-specific signs and symptoms; in 
addition, infected immunosuppressed patients commonly have other opportunistic 
infections [57]. PCP is often the HIV/AIDS indicator disease and should be suspected in 
all HIV-positive patients with respiratory symptoms [42].  
 
1.2.2.1 Clinical and radiological diagnosis 
A chest x-ray of a patient with early presentation of PCP may show a perihilar haze, and 
late presentation generally shows bilateral interstitial infiltration [3;51-53]. This can 
progress to dense, diffuse alveolar infiltrates if the patient is not treated or is treated 
unsuccessfully. PCP is often diagnosed clinically, especially in SA, but the value of this is 
debatable [47;50;51]. A low CD4 cell count, specifically less than 200 cells/mm3, is a risk 
factor for PCP, but infection can occur in patients with CD4 cell counts greater than 200 
cells/mm3 [14;38;47;50-52;58]. The CD4 count is less valuable in HIV-negative patients 
with PCP, who can have counts from 42 to 900 cells/mm3 [59]. 
 
1.2.2.2 Laboratory diagnosis 
Laboratory diagnosis is important because of the non-specific signs and symptoms of PCP 
[51]. A number of different methods have been explored for the diagnosis of PCP because 
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the organism cannot be maintained in culture. In the past, various stains were used to 
identify Pneumocystis organisms. These included Grocott’s methenamine silver, toluidine 
blue O, cresyl violet and Giemsa stains [50;53;60].  
 
Identification methods have naturally evolved over time. Electron microscopy has 
successfully shown the trophozoite, sporocyte and cyst stages of Pneumocystis in 
respiratory specimens, but because of its precise and lengthy processing steps, it cannot be 
used to routinely diagnose PCP. In recent times, the most commonly used diagnostic 
methods for PCP are indirect immunofluorescence assay (IFA) and polymerase chain 
reaction (PCR). For IFA diagnosis, broncho-alveolar lavage (BAL) is recommended in 
order to obtain a reliable result [42;51]. However, an induced sputum, which has been 
shown to have a good yield, may also be used [61]. The invasive procedures required to 
obtain these specimens, puts the already weak patient under further stress so measures 
must be taken to monitor the patient during the procedure.  
 
Other respiratory specimens may be used for IFA but the sensitivity of the test will 
decrease. Due to the nature of the disease, patients are not often able to expectorate sputum 
samples. The sputum induction procedure can only be carried out by a trained nurse. For 
this, the patient must inhale a mist of hypertonic saline created by a nebulizer. As arterial 
blood desaturation may result, the patient’s arterial blood saturation should be measured 
with a pulse oximeter  during sputum induction [53]. This technique was used to collect the 
samples for this study.  
 
PCR assays are used, but as they are very sensitive [especially quantitative real-time PCR  
(qPCR)], they identify colonisation in addition to infection which may make the results 
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less valuable [51]. DNA copy number cut-offs to differentiate colonisation and infection, 
for qPCR assays have been suggested but need to be standardised for routine use [51;62-
64]. Colonisation studies should make use of qPCR assays, or results may be questionable. 
An example is a study that found a low rate of colonisation in HIV-infected adults and 
their children [65], but this may be because they used a nested PCR instead of a qPCR, 
which is more sensitive. Due to the sensitivity of PCR, a variety of specimen types have 
been successfully used to identify the presence of P. jirovecii, such as induced sputum, 
broncho-alveolar lavage, oral wash and tracheal aspirate specimens [66-68]. Whichever 
method is used to identify P. jirovecii, the results should be coupled with the clinical 
presentation of the patient, especially because of colonisation [69]. 
 
Molecular methods have also been employed to determine drug resistance levels, because 
in-vitro susceptibility tests cannot be done due to the lack of a culture system. With respect 
to PCR, it must be remembered that this method and other related molecular methods do 
not identify the whole organism, as most histologic methods do [70;71].  
 
DNA extraction is a method that is carried out prior to DNA molecular analysis [72]. It is 
important that the DNA is isolated carefully to ensure that it is not fragmented. The typical 
extraction procedure involves cell disruption to free the DNA, removal of contaminants 
namely RNA and proteins, and precipitation of the DNA. This is done in the presence of a 
chelating agent which binds to the magnesium ions, which are needed by the DNA 
degrading enzymes (DNases). DNA extraction methods have developed over time; some 
methods involve the use of magnetic beads and others use spin columns [73;74]. Several of 
these methods have been incorporated into automated systems thereby creating an easy-to-
use procedure.  
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Some serum markers have been found to be associated with PCP but the diagnostic 
significance is unclear. The first is lactate dehydrogenase (LDH) which has been shown to 
increase in patients with PCP, but it has also been noted that this increase is probably due 
to the lung inflammation and injury associated with PCP rather than the disease itself 
[42;47;52]. The second marker is (1->3) -D-glucan (BDG), which forms part of the cell 
wall of most fungi and has been used as a serum marker for other fungal diseases; therefore 
again this marker is not specific to PCP. However, many studies have shown that BDG can 
be a useful marker for PCP, especially if coupled with the clinical presentation of the 
patient [14;38;75;76]. Testing for these serum markers to diagnose PCP is an option but 
due to the non-specific nature of the tests it may not be practical [57;77].  
 
The essential metabolite S-adenosylmethionine (SAM) cannot be synthesised by 
Pneumocystis, as it is by other organisms. For this reason, determining the level of SAM in 
people infected with P. jirovecii was investigated as another promising test for PCP. It was 
successfully shown that SAM levels became depleted during PCP infection and after 
treatment, levels of SAM increased [78]. On the contrary, other investigators found that 
SAM was not a reliable marker for PCP [79]. 
 
1.2.3 Prophylaxis and treatment 
Patients with severe immunodeficiency should receive PCP prophylaxis [47;58]. In SA 
guidelines stipulate that all patients with CD4 cell counts 200 cells/mm3 should be given 
PCP prophylaxis [80]. This is usually in the form of the sulfa-containing drug 
trimethoprim-sulphamethoxale (TMP-SMX or cotrimoxazole). This drug also provides 
protection against another opportunistic pathogen – Toxoplasma gondii, as well as many 
bacterial infections. The most common side effect of this drug is a maculopapular rash that 
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develops more frequently in HIV-positive patients. An antihistamine can be prescribed, to 
reduce this reaction or the patient can be desensitised. However, in the case of other more 
serious side effects such as fever, hepatitis and mucous membrane lesions, an alternative 
drug should be used. Dapsone is an alternative to TMP-SMX.  
 
Treatment drugs for PCP are very similar to the PCP prophylactic drugs. Cotrimoxazole is 
the first choice [47;49;68]. Dapsone plus trimethoprim or clindamycin plus primaquine can 
be used in cases of adverse reactions to TMP-SMX. Atovaquone and pentamidine are other 
choices. Pentamidine has been linked to worse outcome compared to TMP-SMX and 
clindamycin plus primaquine [81]. Adjunctive steroids such as prednisone should be given 
to reduce the host inflammatory response. 
 
PCP prophylaxis or treatment is not always effective for reasons including side effects 
such as toxicity, treatment failure and non-adherence [18;82;83]. Heffelfinger et al. [82] 
conducted a large study in America to determine the extent and reasons for non-adherence. 
They found that 18% of patients were non-adherent and the most common factors 
associated with non-adherence were drug abuse and mental health problems. In SA, non-
adherence is also a problem, but for reasons far different. The main reason is limited or no 
access to medication. 
 
Some studies have shown that cotrimoxazole prophylaxis decreases the incidence of PCP 
in HIV-patients [84;85]. A South African study that showed that children on PCP 
prophylaxis were less likely to develop PCP compared to those not on these drugs [42]. 
However, another study in SA proved that this is not always the case. In 2002, Madhi et al. 
[86] carried out a study on South African children with pneumonia. They found that 
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children who received TMP-SMX prophylaxis did not have a significantly reduced number 
of PCP episodes compared to children who did not receive prophylaxis. However, they did 
find that PCP patients who were on PCP prophylaxis had a better outcome than those who 
were not. 
 
1.2.4 Epidemiology 
1.2.4.1 Global PCP 
PCP was the most common opportunistic infection in HIV/AIDS patients in developed 
countries such as the United States of America (USA) [40;87]. For this reason, when the 
HIV burden was at its highest, the number of PCP cases increased. However, due to 
effective public health interventions, namely PCP prophylaxis and HAART, PCP has 
decreased in most developed countries [40;46;87;88]. A study in the USA analysed 
national data over a 20-year period from 1986 to 2005, and showed that hospitalisation and 
hospital mortality for AIDS-associated PCP has decreased over this period. This period 
included the introduction of chemoprophylaxis and potent combination antiretroviral 
therapy [40]. PCP continues to be a major health problem among people who are unaware 
of their HIV status, have limited or no access to treatment, and do not adhere to 
antiretroviral therapy or PCP prophylaxis [18;47;51]. 
 
It was initially believed that PCP in HIV-positive patients, was not as prevalent in Africa 
and the rest of the developing world, compared to the developed world. However, more 
recently, studies have proven otherwise and reasons for the earlier findings, such as small 
study groups, have been proposed [42;47;58;89-91]. Studies carried out in Zimbabwe 
(1992-1993), Kenya (1999-2000), Uganda (1999-2000) and Ethiopia (2004-2005) on HIV-
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positive adult patients who were sputum smear-negative for AFB, documented PCP 
prevalence rates of 33% (31/64), 37% (19/51), 39% (32/83) and 30% (39/131), 
respectively [58;90;92;93].  
 
1.2.4.2 PCP in South Africa 
PCP is of great concern in SA because of the burden of HIV/AIDS [89]. There are a 
limited number of published articles regarding PCP in SA, especially in adults. Wood et al. 
[100], found 22% of HIV-positive clinic attendees in the Western Cape had PCP, the 
second highest HIV-related disease after TB [91;94]. A post-mortem study done on the 
bodies of HIV/AIDS patients in the Eastern Cape found a 9% PCP prevalence [95]. 
Ramogale et al. [96] reported that pneumonia (PCP and bacterial) was the second highest 
cause of maternal deaths in a hospital in KwaZulu-Natal, SA. Ten percent of acute 
pneumonia cases in HIV-positive children were due to PCP in 1998 [42],  and a similar 
study carried out in 2006 to 2008 found a 21% prevalence [43]. From these data, we can 
conclude that PCP is a major health problem in our country. 
 
1.3 Resistance  
1.3.1 Mechanism of resistance  
As with many organisms, drug resistance has become an important problem. 
Pneumocystis jirovecii has been shown to have potential resistance to sulfa drugs. If 
confirmed, resistance will reduce the efficacy of these widely-used drugs [97].  
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Sulphonamide drugs have been used for over 60 years and are effective because they target 
the enzymes utilised in the folate synthesis pathway [98]. Many microorganisms, including 
P. jirovecii, need to produce their own folate as they are not able to transfer it into their 
cells. The multifunctional fas (folic acid synthesis) gene codes for the enzymes 
dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and DHPS 
[99], which are required for folate synthesis. Sulfa drugs inhibit these enzymes and since 
humans do not have these enzymes, they are not adversely affected. Mutations in the fas 
gene are thought to alter the enzyme’s structure and therefore sulfa drugs are not as 
effective, as their active binding site has been modified [84]. Figure 1.4 illustrates the 
possible mechanism of resistance caused by mutations in the DHPS region of the fas gene, 
which will further be referred to as the DHPS gene for simplicity. 
 
Two DHPS mutations in P. jirovecii that are thought to be associated with sulfa resistance 
are non-synonymous point mutations at nucleotide positions 165 and 171 [37;100;101]. A 
mutation at position 165 (from adenine to guanine) causes an amino acid change from 
threonine to alanine at codon 55 and a mutation at position 171 (from cytosine to thymine) 
causes a change from proline to serine at a codon 57. Combinations of both mutations have 
also been seen. These DHPS mutations have been linked to sulfa drug resistance in other 
organisms such as Plasmodium falciparum, Neisseria meningitidis, Streptococcus 
pneumoniae and Streptococcus pyogenes, which shows that this highly-conserved region is 
a common target for mutations that can cause drug resistance [102-105].  
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             (A)           (B)                         (C)  
 
Figure 1.4 Mechanism of P. jirovecii resistance to sulfa drugs caused by mutations in the DHPS region of the fas gene (Graphic by B. Poonsamy) 
(A): Normal scenario - DHPS enzyme catalyses the condensation of pABA and pteridine to form dihydropteroic acid. Further steps in this 
pathway lead to folic acid synthesis and eventually DNA synthesis, hence the organism continues to survive. (B): Treatment with sulfa drugs - 
Sulfa drugs are chemical analogues of pABA and bind to DHPS, thus competitively inhibiting the enzyme and folate synthesis resulting in the 
death of the organism. (C) DHPS mutations - DHPS gene mutations are thought to cause structural changes in the enzyme’s substrate binding 
site, which interferes with sulfa binding and possibly causes sulfa resistance, thereby allowing folic acid synthesis to continue as normal. 
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1.3.2 Global P. jirovecii DHPS mutation patterns 
Published data show that DHPS mutations in P. jirovecii are more prevalent in developed 
countries, with prevalence rates ranging between 0 - 81%  [14;34-37;67;100;101;106-121]. 
In comparison, mutation rates in developing countries range from 0 - 12% [34;35;122-
128]. This correlates with the findings on PCP infection prevalence in developing countries 
and is probably due to the limited use of sulfa drugs. It may also be related to the limited 
number of studies and the small sample sizes used. The mean sample size in the studies 
from developed countries was 100 (range, 6 - 394), compared to a mean sample size of 24 
(range, 6 - 57) in the developing countries’ studies. Two studies in South Africa used 
larger sample sizes (79 and 151) and found substantially higher DHPS mutation rates (38% 
and 56% respectively) [68;129]. 
 
The highest prevalence of DHPS mutations has been found in North America, particularly 
the USA. Studies in Europe show varying prevalence, and studies in South America are 
limited. Except for the two studies from our group [68;129], the prevalences of mutations 
in Africa, Asia and Australia are low (Figure 1.5). 
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Figure 1.5  Comparison of the prevalence of DHPS mutations in P. jirovecii studies carried out on different continents** [14;34-
37;67;68;100;101;106-112;114-129] 
**Key: Red bars = North America, Yellow bars = Europe, Green bar = Oceania, Blue bars = Asia, and purple bars = Africa. NS = not stated, * = developing countries. 
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1.3.3 DHPS mutations, sulfa prophylaxis and patient outcome  
Many studies have shown that DHPS mutations are more likely to occur as a result of sulfa 
drug prophylaxis failure or more generally, in patients that have been previously exposed 
to sulfa drugs [35;67;101;106;113;116;118;119;130]. The theory of these mutations arising 
from selective pressure of sulfa drugs has been supported by other studies [34;35]. A study 
in Spain found a higher rate of DHPS mutations in the pre-combined antiretroviral therapy 
(pre-cART) period compared to the cART period, and these mutations were associated 
with previous sulfa drug prophylaxis [36]. However, DHPS mutations have also been 
found in patients who have not been exposed to sulfa drugs [110], which again suggests 
person-to-person transmission of P. jirovecii.  
 
In developed countries prophylactic drugs are more commonly administered and this is the 
most plausible reason for the high rates of DHPS mutations in these countries. Kazanjian et 
al. [34] showed that in the USA where sulfa drugs are widely used, the prevalence of 
DHPS mutations was higher (40%) compared to China (7%) where using prophylactic 
sulfa drugs for PCP is not common. This strongly suggests that the drugs select for the 
mutations.  
 
Studies in SA have found a range of prevalence of DHPS mutations (Table 1.1). The two 
more recent studies [68;129] showed that a high prevalence of P. jirovecii DHPS mutations 
in patients from SA exists. It is possible that in SA we have an emerging sulfa drug 
resistance problem, as sulfa drugs are now being more widely used. 
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Table 1.1 P. jirovecii DHPS mutation studies conducted in South Africa [68;124;125;129] 
Year of 
publication 
Province/s of 
study 
Year/s of 
study 
Study 
population 
Samples with 
DHPS mutant 
genotypes* 
(number) 
2004 Western Cape Not stated HIV-positive 
children 3% (1/30) 
2005 
KwaZulu-Natal, 
Western Cape, 
Eastern Cape, 
North West and 
Mpumalanga 
2000-2003 Not stated 2% (1/53) 
2006 Gauteng 2004 HIV-positive 
adult inpatients 38% (30/79) 
2010 
Gauteng (69%); 
Eastern Cape, 
Mpumalanga, 
Free State, 
Limpopo, 
Northern Cape 
2006-2007 
Adults and 
children (HIV 
status unknown) 
56% (85/151) 
*Includes only mutations at nucleotide positions 165 and 171. 
 
The important question of whether these mutations have an impact on patient outcome 
remains unanswered. Published data to date provide conflicting evidence. Reasons for this 
include inconsistent study definitions (e.g., for treatment outcome or previous exposure) 
and small data sets [84;113;131]. These reasons also explain why much else is unclear with 
regard to PCP. Several studies have found that patients harbouring P. jirovecii with mutant 
DHPS genotypes present with more severe disease and have a worse outcome 
[108;112;113;116], while others found that mutations were not associated with adverse 
patient outcome [36;114]. Valerio et al. [110] showed that DHPS mutations were 
associated with possible sulfa drug treatment failure. 
 
  1.3.4 Identification of DHPS mutations 
To identify the DHPS mutations, a number of molecular processing options are available, 
such as sequencing, restriction fragment length polymorphism (RFLP) and single strand 
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conformation polymorphism (SSCP) [101;111;132]. However, all these methods have the 
limitation of not being able to resolve the complex mixed DHPS genotypes. These mixed 
genotypes can be resolved if their PCR products are cloned into an appropriate vector, 
amplified by PCR and sequenced.  
 
Many studies that examined DHPS genotypes found that some patients harboured these 
complex mixed P. jirovecii DHPS genotypes [68;106;109;110;129]; therefore there is a 
need to resolve these genotypes. By resolving these mixed genotypes, we can re-group 
PCP patients according to their specific DHPS genotype and look for a possible link 
between DHPS genotype and patient outcome. We can possibly determine if patients with 
one P. jirovecii strain containing double mutants have a different outcome compared to 
patients with two P. jirovecii strains containing single mutants. It is possible that 
P. jirovecii strains with double mutations have increased resistance compared to strains 
with single mutations, as has been found with P. falciparum [84].  
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1.4 Study aim and objectives 
 
 
Aim: To resolve mixed DHPS genotypes in Pneumocystis jirovecii in induced sputum 
specimens collected from patients suspected of having Pneumocystis pneumonia. 
 
Objectives:   
1. To validate the Roche MagNA Pure Compact automated extraction system. 
 
2. To determine the fungal load present in each patient specimen with a quantitative 
real-time PCR assay, in order to identify the patients infected with P. jirovecii.  
 
3. To sequence a fragment of the DHPS region of the P. jirovecii fas gene in these 
patients, thereby determining the DHPS genotypes and identifying patients 
harbouring complex mixed DHPS genotypes. 
 
4. To resolve the complex mixed DHPS genotypes by cloning and resequencing the 
DHPS gene. 
 
5. To determine if there is any association between DHPS genotype and in-hospital 
patient outcome. 
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CHAPTER 2 - MATERIALS AND METHODS 
 
2.1 Patient recruitment, sample and clinical data collection  
This project forms part of a larger study entitled “Survey and management of drug-
resistant Pneumocystis jirovecii in South Africa”. Patient recruitment started in March 
2005 and concluded in June 2009. Adult patients admitted to the Respiratory Unit at the 
Chris Hani Baragwanath (CHB) Hospital, who were clinically suspected of having 
Pneumocystis pneumonia, were invited to enrol in the study. Once informed consent was 
obtained (Appendix A), an induced sputum sample was taken by a qualified study nurse. 
Repeat specimens were taken on request from the clinician. The enrolled patients were 
monitored and clinical data were collected (Appendix B) until the patient was discharged 
or died. All clinical data were analysed for the larger study; for this project, only in-
hospital patient outcome information was analysed.  
 
2.2 Pneumocystis jirovecii diagnosis 
2.2.1 P. jirovecii diagnosis by IFA 
P. jirovecii diagnosis was done by the Parasitology Reference Unit (PRU) of the National 
Institute for Communicable Diseases (NICD). This accredited national reference laboratory 
is the largest P. jirovecii testing laboratory in the country and hence was well placed to 
carry out testing. Specimens were pre-digested by adding equal volumes of a 1.4-
dithiothreitol (DTT) (Roche Diagnostics GmbH, Mannheim, Germany) working solution 
(Appendix C) to the specimen. Specimens were vortexed well for at least 30 seconds and 
incubated at 37°C for 15 minutes. This allowed the DTT to digest the sputum by breaking 
down any mucus present in the specimen. After incubation, specimens were vortexed again 
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and if clumps of mucus were still present, 1 ml of DTT stock (65 mM) (Appendix C) was 
added and the specimen was incubated at 37°C for a further 15 minutes. 
 
To concentrate the specimen, the digested sputum was transferred to a 15 ml centrifuge 
tube and topped up to 14 ml with PBS pH 7.2 (Diagnostic Media Products, NHLS, SA). 
This was centrifuged at 2 000 rpm for 5 minutes. The supernatant was decanted and the 
pellet was resuspended in the remaining liquid. This suspension was applied thinly to a 
well of a clean slide with a pipette. Slides were air dried for 20 minutes and thereafter fixed 
with methanol for 2 minutes. After the methanol evaporated, 40 µl of stain from the Light 
Diagnostics Direct Immunofluorescence Assay (DFA) kit for the detection of P. jirovecii 
(Millipore Corporation, Billerica, MA 01821) was pipetted onto the well and carefully 
spread over the entire well surface. Slides were incubated in a humid chamber at 37°C for 
30 minutes. The stain contained anti-P. jirovecii monoclonal antibodies that were labelled 
with fluorescein isothiocyanate (FITC). The antibodies bound to cysts and trophozoites of 
P. jirovecii. After incubation, excess stain was removed and the slide was washed twice in 
wash buffer (supplied in the Light Diagnostics DFA Kit). One drop of mounting medium 
(supplied in the Light Diagnostics DFA Kit) was added to the well and a coverslip was 
placed on the well.  
 
The entire well was examined with an ultraviolet (UV)-equipped microscope under 400x 
magnification for any fluorescing antibody-antigen complexes. The presence of fluorescent 
green cysts and/or clusters of cysts on a red-stained background confirmed the presence of 
P. jirovecii (i.e. a positive result). The typical clusters of cysts have a honeycomb 
appearance (Figure 2.1). The parasite load was quantified into the following categories for 
the positive specimens:  
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• +  : 2 cysts/ clusters of cysts,  
• ++  : >2-10 cysts/ clusters of cysts, and 
• +++  : >10 cysts/ clusters of cysts. 
If only one cyst or cluster of cysts was observed, a possibly positive result was reported. If 
no cysts or clusters were seen and there was sufficient background staining, a negative 
result was reported. 
 
Figure 2.1 Micrograph showing two fluorescent green clusters of P. jirovecii cysts on a 
red-stained background, 400x magnification 
 
For quality control, positive and negative control slides were stained with every new kit 
used. In addition a positive control slide was stained every week. Tests were repeated if the 
controls failed, the background was insufficient or the slide appeared cloudy under 
magnification. 
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Sample washing  
To prepare samples for molecular analysis, samples were washed to remove reagents such 
as DTT from the sample. This was done by adding 10 ml of 10x PBS (Diagnostic Media 
Products) to the digested, concentrated samples, vortexing and centrifuging at 3 000 rpm 
for 5 minutes. The supernatants were decanted; the pellet was resuspended in the 
remaining liquid (about 200 µl) and the suspension was transferred to a 1.5 ml labelled 
tube, and then stored at -20°C. 
 
2.2.2 Validation of the Roche MagNA Pure Compact 
An automated DNA extraction instrument, the Roche MagNA Pure Compact (RMPC) 
(Roche Diagnostics), was purchased for this study and for other routine work of the PRU. 
In keeping with good laboratory practice, the new piece of equipment was validated. The 
validation formed part of this project. A series of experiments (Experiments 1 – 7) was 
conducted to assess the RMPC for contamination, repeatability and efficiency, in 
comparison with the previously used manual extraction method with the QIAamp DNA 
Mini Kit (Qiagen Inc, Valencia, CA 91355).  
 
The automated RMPC method makes use of preloaded reagent cartridges and robotic 
transfer of the sample from one well to the next. This method uses magnetic glass particles 
(MGP), which extract the DNA (Figure 2.2). The Qiagen (manual) method makes use of 
spin columns. First the organism is lysed to release the DNA, the DNA is then bound to the 
QIAamp silica membrane and washed twice to remove any residual contaminants, thereby 
improving the purity of the DNA. Lastly, the purified DNA is eluted from the QIAamp 
spin column in a concentrated form (Figure 2.3). 
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Figure 2.2 Principle of nucleic acid extraction in the Roche MagNA Pure Compact [133] 
 
 
Figure 2.3 Principle of nucleic acid extraction with the Qiagen DNA Mini Kit. Adapted 
from the Qiagen DNA Mini Kit handbook [134]. 
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Cross-contamination in the RMPC (Experiment 1) 
When extracting DNA with the Qiagen method, specimens were handled individually, to 
prevent contamination. However, in the RMPC all specimens (up to eight) were open and 
processed simultaneously; this led to the question of possible cross-contamination due to 
aerosols. To check for cross-contamination in the RMPC, four highly positive specimens 
and four negative samples (sterile water) were placed in alternating positions in the RMPC 
and processed. The method used is detailed in section 2.2.3.1. A qPCR (as described in 
section 2.2.3.2) was performed on all eight extracted DNA specimens to determine the 
copy number of any P. jirovecii DNA present.  
 
Comparison of the automated RMPC versus the manual Qiagen method (Experiment 2) 
To compare these automated and manual extraction methods, 12 IFA-positive and 12 IFA-
negative specimens were extracted with both methods. The manual extraction method used 
is detailed in Appendix D. All extracted DNA were processed further by a qPCR assay. 
 
Technical optimisation of the use of the RMPC reagents (Experiment 3) 
When performing automated DNA extractions, it was noticed that the well containing the 
magnetic beads in the reagent cartridge (Figure 2.4) had varying amounts of beads at the 
bottom of the well. In some cartridges the beads had adhered to the sides of the well. As 
the magnetic beads form a crucial part of this automated extraction method, this 
experiment was designed to compare the effect of shaking the cartridges to ensure all the 
magnetic beads were at the bottom of the cartridges before use, as opposed to not shaking 
the cartridges. 
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Figure 2.4 Roche MagNA Pure reagent cartridge needed for DNA extraction with the 
Roche MagNA Pure Compact [133] 
 
The same 12 positive specimens from Experiment 2 were extracted again but in this 
experiment each cartridge was shaken well before being loaded into the RMPC. The 
extracted DNA from the 12 positives from Experiment 2 (in which the cartridges were not 
shaken) and the newly extracted DNA (cartridges shaken) were amplified by qPCR. 
 
Repeat of the comparison of the automated RMPC versus the manual Qiagen method 
experiment (Experiment 4) 
Following the previous experiment, the results of the comparison experiment may have 
been influenced by the cartridges not being shaken. Therefore, the qPCR was repeated on 
the DNA extracted manually and the DNA extracted by the RMPC with the cartridges 
shaken. 
 
Robustness (Experiment 5) 
The starting volume which is the volume of washed sputum that is digested, and the 
loading volume, which is the volume of digested material that is loaded into the RMPC, 
can be altered. In order to determine the optimal starting and loading volumes, the same 
positive specimen was processed at starting volumes of 20 µl and 50 µl and loading 
Well containing 
magnetic beads 
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volumes of 100 µl and 200 µl. A qPCR assay was performed on the extracted DNA to 
determine any differences in DNA copy number. 
 
Repeatability (Experiment 6) 
To test for repeatability three specimens with a low, medium and high copy number of 
DNA respectively were processed in triplicate with both the RMPC and Qiagen extraction 
methods. A qPCR assay was performed on the extracted DNA. 
 
Varying instrument protocols (Experiment 7) 
Roche Diagnostics suggested using a different protocol on the RMPC called the bacterial 
protocol [previously the total nucleic acid (NA) protocol was used], which they loaded 
onto the RMPC. The results of the two protocols on the RMPC were compared with the 
manual extraction method. Three specimens with low, medium and high copy numbers 
were processed in triplicate with the three methods; a qPCR assay was performed on the 
extracted DNA. 
 
2.2.3 P. jirovecii diagnosis by real-time PCR  
2.2.3.1 DNA extraction 
Following the validation, all specimens were extracted with the automated RMPC. 
Respiratory specimens were first digested by adding 150 µl of bacterial lysis buffer (Roche 
Diagnostics) and 20 µl of proteinase K (Roche Diagnostics) to 50 µl of the washed sample. 
This was incubated for 2 hours at 56°C. DNA was extracted with the RMPC and the 
MagNA Pure Compact Nucleic Acid isolation kit (Roche Diagnostics), as per the 
manufacturer’s instructions. Samples were loaded into the instrument and the bacterial 
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lysis protocol was selected. The 100 µl of extracted DNA were frozen at -70°C. For quality 
control, positive and negative controls were included in each extraction run. 
 
2.2.3.2 Quantitative real-time PCR  
Fungal load was determined with a qPCR assay [129] targeting a region coding for the 
mitochondrial large subunit (MtLSU) rRNA with an Applied Biosystems 7500 real-time 
PCR instrument (Applied Biosystems, Foster City, CA 94404).  
 
In each assay, the final 25 µl reaction mixture consisted of 12.5 µl of 1x TaqMan universal 
master mix (Applied Biosystems), 0.25 µl of primer/probe mix at 20 µM each (1 part 
forward primer: 1 part reverse primer: 1 part MGB probe: 2 parts water) (Table 2.1), 2.5 µl 
of 10x Exo IPC (internal positive control) Mix, 0.5 µl of 50x Exo IPC DNA, 4.25 µl of 
water and 5 µl of DNA. The master mix was pipetted into 96 well MicroAmp plates 
(Applied Biosystems). Each plate contained standards (Appendix C) which were 
performed in triplicate, and included 10-10 (17 copies), 10-9 (170 copies), 10-8 (1 700 
copies), 10-7 (17 000 copies) and 10-6 (170 000 copies) dilutions. Plates also contained 
negative or NTC (no target template control) wells and an IPC block well. Plates were 
covered with an adhesive optic film (Applied Biosystems) and centrifuged at 2 800 rpm for 
5 minutes. The plate was loaded into the 7500 PCR instrument and an absolute 
quantification (standard curve) assay was setup on the Applied Biosystems SDS v1.3.1 
program. Detectors FAM and VIC and the passive reference ROX were selected. The PCR 
assay parameters were as follows: 2 minutes at 50°C, 10 minutes at 95°C, followed by 45 
cycles of 15 seconds at 95°C and 1 minute at 60°C. Quantification was based on 
extrapolation to standard curves generated by amplification of the standards. The standards 
were serial dilutions of a linearised plasmid (pCR2.1) which contained the P. jirovecii 
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DNA fragment defined by primers LSU1 and LSU2 (Table 2.1). The result analysis was 
done with the 7500 System Software. Real-time PCR results were expressed as target 
sequence copy number per 5 µl, further referred to as DNA copy number. For quality 
control, IPC controls, PCR positive controls and positive and negative DNA extraction 
controls were included in each real-time assay. An RNAse P PCR to detect inhibition 
(Appendix G) was done on all IFA-positive specimens that were qPCR negative. 
 
Table 2.1 Primers used for P. jirovecii PCR assays [129] 
PCR Primer/probe name Oligonucleotide sequence 
Real-time qPCR Primer LSU1 
(forward) 
5´-AAA TAA ATA ATC AGA CTA TGT 
GCG ATA AGG-3´ 
Real-time qPCR Primer LSU2 
(reverse) 
5´-GGG AGC TTT AAT TAC TGT TCT 
GGG-3´ 
Real-time qPCR Probe LSUP1 FAM 5´-AGA TAG TCC AAA GGG AAA 
C-3´TAMRA (Applied Biosystems) 
Nested DHPS PCR 
– primary  
Primer SMIF1  
(forward) 
5’ CAA ATT AGC GTA TCG AAT GAC C 
3’ 
Nested DHPS PCR 
– primary 
Primer SMIB2  
(reverse) 
5’ GCA AAA TTA CAA TCA ACC AAA 
GTA 3’ 
Nested DHPS PCR 
– secondary and 
Cycle sequencing 
Primer SMIF6 
(forward) 
5’ AGC GCC TAC ACA TAT TAT GG 3’ 
Nested DHPS PCR 
– secondary 
Primer SMIB7  
(reverse) 
5’ GTT CTG CAA CCT CAG AAC G 3’ 
Cycle sequencing* Primer Mini-B7 
(reverse) 
5’ CTG CAA CCT CAG AAC G 3’ 
* Unpublished 
 
2.3 Primary sequencing  
2.3.1 Nested PCR 
All real-time PCR positive specimens (i.e. DNA copy number >0) were selected for further 
processing. The DHPS gene was amplified by a nested PCR (nPCR) protocol [129] in an 
Eppendorf Mastercycler (Eppendorf, Hamburg, Germany).  
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In each primary PCR assay, the final 25 µl reaction mixture consisted of 10.75 µl of water, 
2.5 µl of 10x buffer, 2.5 µl of 1.25 mM dNTPs, 3 µl of 25 mM MgCl2, 0.5 µl of 50 µM 
primer SMIF1 (Table 2.1), 0.5 µl of 50 µM primer SMIB2 (Table 2.1), 0.25 µl (5U/µl) 
Supertherm Taq DNA polymerase and 5 µl of DNA.  
 
PCR tubes were loaded into the Eppendorf Mastercycler. The cycling parameters were as 
follows: an initial extended denaturation step at 94°C for 5 minutes, followed by 35 cycles 
of 94°C for 30 seconds for denaturation, 55°C for 1 minute for annealing, 72°C for 2 
minutes for extension and a final extended extension cycle of 72°C for 7 minutes. Primary 
PCR products were stored at 4°C short term until the secondary PCR was performed. For 
long term storage the products were stored at -20°C. 
 
In each secondary PCR assay, the final 25 µl reaction mixture consisted of 14.75 µl of 
water, 2.5 µl of 10x buffer, 2.5 µl of 1.25 mM dNTPs, 3 µl of 25 mM MgCl2, 0.5 µl of 
50 µM primer SMIF6 (Table 2.1), 0.5 µl of 50 µM primer SMIB7 (Table 2.1), 0.25 µl 
(5U/µl) Supertherm Taq DNA polymerase and 1 µl of DNA.  
 
PCR tubes were loaded into the Eppendorf Mastercycler. The cycling parameters were as 
follows: an initial extended denaturation step at 94°C for 5 minutes, followed by 35 cycles 
of 94°C for 30 seconds for denaturation, 52°C for 30 seconds for annealing, 72°C for 1 
minute for extension and a final extended extension cycle of 72°C for 7 minutes. 
Secondary PCR products were stored at 4°C short term until gel electrophoresis was 
performed. For long term storage the products were stored at -20°C. 
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For quality control, negative controls were included in each primary and secondary PCR to 
identify any possible contamination. Positive controls were not required as the specimens 
were known positives. 
 
2.3.2 Gel electrophoresis 
PCR products were resolved on a 1.5% agarose gel stained with ethidium bromide. The gel 
was made by adding 0.45 g of agarose to 30 ml 1x TAE buffer (Appendix C). This was 
dissolved in a microwave by heating for 1 minute. After cooling, 1.5 µl of 10 mg/ml 
ethidium bromide was added; the solution was poured into the gel-setting chamber, and left 
to set for 45 - 60 minutes. Five microlitres of PCR product, 1 µl of 6x DNA loading dye 
(Fermentas, Burlington, Ontario, L7N 3N4) and 4 µl of 1x TAE buffer were mixed and 
loaded into the wells. Four microlitres of a Generuler 100 bp plus DNA ladder (Fermentas) 
was added to the first well of the gel. Samples were run at 110 volts for at least 35 minutes. 
The gel was viewed with an ultraviolet transilluminator (GelDoc, Vacutec, Johannesburg, 
South Africa) to observe if the 278 bp amplicon was present. 
 
2.3.3 Sequencing of PCR products 
Following amplification, nPCR products were purified with the QIAquick PCR 
purification kit (Qiagen Inc). Five volumes (100 µl) of Buffer PB were added to 1 volume 
(20 µl) of the PCR sample. This was vortexed and briefly centrifuged. To bind the DNA, 
the sample was applied to the QIAquick column (in 2 ml collection tube) and centrifuged 
for 60 seconds. The flow-through was discarded and the collection tube was blotted to 
remove excess fluid. The QIAquick column was placed back into the same tube and 
washed by adding 750 µl of Buffer PE to the column and centrifuging for 60 seconds. This 
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step was repeated and the tube was centrifuged for an additional 1 minute to remove any 
residual ethanol from Buffer PE. The QIAquick column was placed in a clean labelled 1.5 
ml microcentrifuge tube, and the collection tube was discarded. To elute DNA, 25 µl of 
Buffer EB was added to the centre of the QIAquick membrane. The column was left to 
stand for 1 minute, and then centrifuged for 1 minute. The column was discarded and the 
purified product was stored at 4°C for a short while, if the sequencing reaction was not 
done immediately. 
 
Sequencing was done in both directions with the BigDye v3.1 Terminator Cycle 
Sequencing Kit (Applied Biosystems). Each cycle sequencing reaction had a final volume 
of 10 µl which consisted of 6 µl water, 1 µl of 5x sequencing buffer, 2 µl Big Dye 
terminator v3.1, 0.5 µl of 1 µM primer (SMIF6 or Mini-B7) and 0.5 µl of cleaned PCR 
product. Cycling parameters consisted of 25 cycles of denaturation at 96°C for 20 seconds, 
annealing at 50°C for 15 seconds and extension at 60°C for 4 minutes. Samples were 
stored at 4°C for short term or at -20°C for long term. 
 
Products were purified with the DyeEx 2.0 Spin Kit (Qiagen). The Qiagen spin column 
was vortexed well to remove bubbles from the gel and centrifuged at 2 700 rpm for 3 
minutes to remove the liquid. The spin column was placed in a clean labelled 1.5 ml 
microcentrifuge tube, and the collection tube was discarded. The sequencing product was 
carefully pipetted into the middle of the gel and the tubes were centrifuged at 2 700 rpm 
for 3 minutes. The columns were discarded and the cleaned product was vacuum dried in 
an Eppendorf Concentrator (Eppendorf) for 20 minutes at room temperature. Samples were 
stored at 4°C for short term or at -20°C for long term. 
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Twelve microlitres of Hi-Di Formamide (HDF) was added to the dried purified sample. 
This was vortexed and incubated at 95°C for 2 minutes. Samples were then placed on ice 
for 1 minute, pipetted into a 96 well optical plate which was centrifuged briefly. 
Electrophoresis was performed in an Applied Biosystems 3130 Genetic Analyzer (Applied 
Biosystems), with the ‘Rapidseq36_POP7_3.1’ programme and the ‘3130POP7_BDTv3’ 
analysis protocol. The ‘Sequence analysis software v5.2’ was used to obtain the results and 
the ‘Bioedit Software’ was used to analyse the sequences. 
 
This initial sequencing was referred to as primary sequencing, and the mutations were 
classed and named according to Table 2.2 for simplicity. The genotypes labelled ‘basic 
genotypes’ and ‘resolvable mixed genotypes’ are the DHPS genotypes which could be 
determined from the primary sequencing. The ‘irresolvable mixed genotypes’ are the 
genotypes which were cloned and resequenced in order to discern their DHPS genotypes.  
 
Table 2.2 Different possible primary sequencing DHPS genotype results with their 
corresponding bases at nucleotide positions 165 and 171 and the resulting amino acids at 
codons 55 and 57, respectively 
Name Description 
Base/s at nucleotide 
position 165, and 
resulting amino acid 
at codon 55 
Base/s at nucleotide 
position 171, and 
resulting amino acid 
at codon 57 
Basic genotypes 
WT Wild type, no mutations A, Thr C, Pro 
M1 Single mutation at position 165 G, Ala C, Pro 
M2 Single mutation at position 171 A, Thr T, Ser 
M3 Double mutation G, Ala T, Ser 
Resolvable mixed genotypes 
WT + M1 Mix of wild type and M1 A, Thr/ G, Ala C, Pro 
WT + M2 Mix of wild type and M2 A, Thr C, Pro/ T, Ser 
M3 + M1 Mix of M3 and M1 G, Ala T, Ser/ C, Pro 
M3 + M2 Mix of M3 and M2 G, Ala/ A, Thr T, Ser 
Irresolvable mixed genotypes 
Unknown mix A, Thr/ G, Ala  C, Pro/ T, Ser 
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2.4 Cloning 
Specimens with irresolvable mixed DHPS genotypes were cloned with the TOPO TA 
Cloning® Kit (Invitrogen, Carlsbud, California 92008). To ligate the PCR product into the 
vector, a 6 µl reaction mixture containing 3 µl of water, 1 µl of salt solution (1.2 M NaCl; 
0.06 M MgCl2), 1 µl of pCR®2.1-TOPO® vector (Figure 2.5) (kept on ice) and 1 µl of PCR 
product was prepared. This was incubated at room temperature for 30 minutes.  
 
 
Figure 2.5 pCR 2.1-TOPO® vector, showing restriction sites, used to clone the P. jirovecii 
DHPS gene 
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For the transformation procedure, 3 µl of the ligation mix was added to 80 µl of One Shot® 
TOP10 chemically competent cells (E. coli). This was incubated on ice for 30 minutes. The 
mixture was heat shocked at 42°C for 30 seconds, which enabled the cells to momentarily 
take in the vectors. To maximise the transformation efficiency of competent cells, 250 µl 
of SOC medium was added and this was incubated for 1,5 hours at 37°C in a shaking 
incubator (200 rpm). Forty microlitres of X-gal (40 mg/ml) (Appendix C) was streaked on 
LB plates and kept at 37°C until use. Fifty microlitres of transformed cells were streaked 
onto the plate and incubated at 37°C overnight, preferably for 18-20 hours. For long term 
storage, 3 ml of Luria broth with ampicillin (Appendix C) and 50 µl of the transformed 
cells were incubated at 37°C in a shaking incubator overnight to increase cell count.  
 
A 20 µl master mix was prepared by adding 12.2 µl of water, 2 µl of 10x buffer, 1.6 µl of 
10 mM dNTPs, 2.4 µl MgCl2, 0.8 µl of 20 µM M13 forward primer (M13 primers included 
in TOPO TA Cloning® Kit), 0.8 µl of 20 µM M13 reverse primer and 0.2 µl Taq 
polymerase. A pipette tip was used to pick off white colonies (i.e. transformed cells) and 
inoculate the master mix. The tip was also used to inoculate a patch plate for short term 
storage of the colonies, and 2 ml of Luria broth (clone culture) for long term storage. Eight 
to ten white colonies and one blue colony (which served as a control) from each sample 
was used. Recombinant clones were screened by PCR. The cycling parameters were as 
follows: an initial extended denaturation step at 94°C for 10 minutes, 25 cycles of 
denaturation at 94°C for 30 seconds, annealing at 45°C for 30 seconds, extension at 72°C 
for 1 minute and an extended final extension step at 72°C for 7 minutes. The PCR products 
were run on a 1.5% agarose gel, as previously described. The expected product size was 
480 bp (plasmid size of 202 bp + PCR insert size of 278 bp). Eight to ten random clones 
were selected from the successful clones. These were sent to Inqaba Biotec (Pretoria, 
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South Africa) for sequencing to establish their individual DHPS genotypes. Sequencing 
was done with the M13 forward primer. To differentiate from the initial (primary) 
sequencing, this subsequent sequencing was referred to as secondary sequencing. 
 
The transformed cells (800 µl) that were left overnight in the shaking incubator were added 
to 200 µl of sterile glycerol, mixed well and frozen at -70°C. The plates used for 
recombinant selection were sealed with parafilm and stored at 4°C. LB patch plates were 
incubated overnight at 37°C. After incubation, LB patch plates were sealed with parafilm 
and stored at 4°C. The clone culture (850 µl) was added to 150 µl sterile glycerol, mixed 
well and stored at -70°C. The plates were kept for short term (1-2 weeks) in case they were 
needed again, after which they were discarded. 
 
2.5 Data management and analysis 
Sequences were analysed with the BioEdit sequence alignment editor and compared 
against one of the DHPS gene sequences obtained from Genbank (Accession number 
AF139132). Data were analysed with InStat software; the two-tailed Fisher’s exact test 
was used to determine associations. A p-value less than 0.05 was considered significant. 
 
2.6 Ethical clearance 
All required ethical clearances were obtained from the Committee for Research on Human 
Subjects of the University of Witwatersrand (protocol number M040612, 28/06/2004 – 
Appendix E). Informed written consent was obtained from all patients enrolled in the 
study. Permission to conduct the study was obtained from the Superintendent of CHB 
Hospital. 
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CHAPTER 3 – RESULTS 
 
3.1 Patient recruitment, sample and clinical data collection 
From March 2005 through June 2009, 280 patients were recruited from the CHB Hospital, 
and 320 induced sputum samples were obtained from these patients. Informed consent 
forms were not signed by 14 patients and therefore they were excluded from the study, 
resulting in 306 specimens for analysis.  
 
There were 195 females and 71 males in the study group and the mean patient age was 
35 years (range, 19 – 60). All 259 patients with a known HIV status were HIV positive. 
The in-hospital outcomes of the patients were recorded as follows; 74% (197/266) were 
discharged, 18% (48/266) died and 1% (2/266) refused hospital treatment. No data were 
available for 7% (19/266). 
 
3.2 Pneumocystis jirovecii diagnosis 
3.2.1 P. jirovecii diagnosis by IFA  
Of the 306 specimens tested for P. jirovecii by the IFA detection method, 51% (156/306) 
were IFA positive, 4% (11/306) were IFA possibly positive and 45% (138/306) were IFA 
negative (Figure 3.1). The IFA test could not be completed for one specimen due to a 
laboratory error that occurred during processing; however this specimen was included in 
all further analysis as the DNA extraction was successful. 
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Figure 3.1 Number of specimens collected and immunofluorescence assay results for 
P. jirovecii by year, 2005-2009, Gauteng, South Africa* 
*2005: 10 month period (Mar – Dec), 2009: 6 month period (Jan – Jun) 
 
3.2.2 Validation of Roche MagNA Pure Compact  
All results for the validation experiments are shown in Appendix F. 
 
Cross-contamination in the RMPC (Experiment 1) 
All four positive specimens yielded high copy numbers between 1 100 000 and 
11 600 000. None of the four negative specimens produced a positive qPCR result.  
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Comparison of the automated RMPC versus the manual Qiagen method (Experiment 2) 
From the 12 IFA-negative specimens, 12 were negative by the automated method and 11 
by the manual method. Fourteen copies of DNA were present in one specimen extracted by 
the manual method. From the 12 IFA-positive specimens, all were positive by both 
methods. Overall, the manual method resulted in a significantly higher yield of DNA      
(p-value = 0.01, Wilcoxon matched-pairs signed-rank test). 
 
Technical optimisation of the use of the RMPC reagents (Experiment 3) 
All 12 IFA-positive specimens resulted in higher copy numbers of DNA, when the 
cartridges were shaken compared to when they were not (p-value = <0.05, Wilcoxon 
matched-pairs signed-rank test). Following this experiment, cartridges were shaken as a 
routine step for all subsequent automated extractions. 
 
Repeat of the comparison of the automated RMPC versus the manual Qiagen method 
experiment (Experiment 4) 
Of the 12 IFA-positive specimens, eight produced a higher copy number when extracted 
manually and four when extracted with the robot (cartridges shaken). However, there was 
no significant difference between the two methods (p-value = 0.20, Wilcoxon matched-
pairs signed-rank test). 
 
Robustness (Experiment 5) 
Samples with the higher starting volume and higher loading volume yielded higher copy 
numbers of DNA. 
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Repeatability (Experiment 6)  
The consistency of the copy numbers for each repeated specimen was similar for both 
methods (p-value = 0.09, paired t-test).  
 
Varying instrument protocols (Experiment 7) 
The new bacterial protocol resulted in a better yield of DNA compared to the total NA 
protocol. There was no significant difference between the two RMPC protocols (p-value = 
>0.05, Dunn’s multiple comparisons test), and the RMPC bacterial protocol and the 
Qiagen method (p-value = >0.05), but there was between the RMPC total NA protocol and 
the Qiagen method (p-value = <0.05). Following this experiment, the bacterial protocol 
was used in all subsequent automated extractions. 
 
A comparison between the two extraction methods is shown in Table 3.1. 
 
Table 3.1 Comparison between the Qiagen and Roche MagNA Pure Compact extraction 
methods 
Criteria Qiagen Roche MagNA Pure Compact 
Length 1 - 2 hours excluding pre-digestion 
time of 2 hours 
< 30 minutes excluding pre-
digestion time of 2 hours 
Number of 
specimens 
Any number of specimens can be 
extracted at one time 
Restricted to 8 specimens per run 
(6 excluding controls) 
Labour Labour intensive and greater 
chance of human error 
Less labour intensive and more 
user-friendly 
Cost ±R40 per sample ±R50 per sample 
Maintenance 
of instrument 
N/A Minimal maintenance of RMPC 
required 
 
 
3.2.3 P. jirovecii diagnosis by real-time PCR 
Quantitative real-time PCR was conducted on DNA extracts from all 306 specimens. 
Sixty-seven percent (205/306) of the specimens were positive for P. jirovecii DNA (i.e. 
they had a DNA copy number greater than 0) and 33% (101/306) were negative for 
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P. jirovecii (Table 3.2). Using the IFA method as the gold standard, there were four false 
negatives qPCR results (three IFA positive and one IFA possibly positive). The extracted 
DNA from the three IFA-positive specimens was diluted and the qPCR repeated to 
eliminate the possibility of PCR inhibition due to excess amounts of DNA; the qPCR 
results remained the same. Two of the three specimens were positive for inhibition, when 
DNA was amplified with the RNAse P PCR assay. The IFA slide for the last specimen that 
was stored at 4°C was also reviewed and the green fluorescent objects did not correspond 
with the typical morphology of P. jirovecii. 
 
Table 3.2 Comparison of the P. jirovecii immunofluorescence assay (IFA) and the 
quantitative real-time PCR (qPCR) assay results, 2005-2009, Gauteng, South Africa (N = 
306) 
 
 
 
*The sample without an IFA result (explained previously) was qPCR positive and is not included in the table.  
 
To determine the statistical measures of performance of the qPCR assay, the IFA-possibly 
positive results were combined with the IFA-positive results. Using the IFA test as the gold 
standard, the sensitivity and specificity of the qPCR assay were calculated to be 98% and 
70%, respectively. The positive and negative predictive values were 80% and 96%, 
respectively.  
 
The median copy numbers of DNA correlated with the IFA results (Table 3.3). There were 
three outliers in the 41 IFA-negative, qPCR-positive results (25 799, 33 825 and 147 500 
copies of DNA) that were excluded from the range given in Table 3.3. 
IFA Result   
Positive Possibly positive Negative 
Positive* 153 10 41 qPCR result 
Negative 3 1 97 
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Table 3.3 Median copy number of P. jirovecii DNA for each immunofluorescence assay 
(IFA) result category, for all quantitative real-time PCR (qPCR) positive specimens, 
Gauteng, South Africa, 2005-2009 
 
 
 
 
 
 
 
To determine if there was a seasonal trend in PCP cases, the qPCR-positive specimens 
were plotted according to month of collection (Figure 3.2). 
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Figure 3.2 Number of specimens with positive P. jirovecii quantitative real-time PCR 
(qPCR) results by month and year of collection, 2005-2009, Gauteng, South Africa* 
*2005: 10 month period (Mar – Dec), 2009: 6 month period (Jan – Jun) 
 
IFA result category Median copy number of DNA in qPCR positive 
specimens (range) 
IFA negative 45 (2 – 15 377) 
IFA possibly positive 493 (60 – 2 566) 
IFA positive 12 817 (7 – 704 257) 
   IFA + 195 (7 – 48 923) 
   IFA ++ 1 779 (93 – 56 260) 
   IFA +++ 23 643 (137 – 704 257) 
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3.3 Primary sequencing  
3.3.1 Nested PCR and gel electrophoresis 
The DHPS gene of P. jirovecii was amplified by nPCR for all specimens with a qPCR-
positive result, and the products were resolved by agarose gel electrophoresis. The product 
size was 278 base pairs (Figure 3.3). The results showed that 84% (173/205) of the qPCR 
positives were positive, and 16% (33/205) negative, by the nPCR assay (Table 3.4).  
 
 
Figure 3.3 Agarose gel showing PCR-amplified 278 base pair product of the P. jirovecii 
DHPS gene*  
*Lanes 1 and 25: 100 bp molecular weight marker, lanes 2-7, 10-15, 17-20: positive results, lanes 8-9, 16: 
negative results, and lanes 21-24: primary and secondary PCR negative controls. 
 
 
Table 3.4 Comparison of the P. jirovecii immunofluorescence assay (IFA) and the nested 
PCR (nPCR) assay results, 2005-2009, Gauteng, South Africa (N = 206) 
 
IFA Result   
  
  
  Positive Possibly positive Negative 
Positive* 145 8 19 nPCR result 
Negative 8 2 23 
 
*The sample without an IFA result (explained previously) was nPCR positive and is not included in the table.  
 
  278    
  base 
  pairs 
  1    2    3    4    5    6    7     8    9   10  11  12  13  14  15  16  17  18  19  20  21  22  23  24   25   
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To determine the statistical measures of performance of the nPCR assay, the IFA-possibly 
positive results were combined with the IFA-positive results. Using the IFA test as the gold 
standard, the sensitivity and specificity of the nPCR assay were calculated to be 94% and 
55% respectively. The positive and negative predictive values were 89% and 70% 
respectively. The nPCR tended to be positive for specimens with high copy numbers (14 - 
704 257) and negative for specimens with low copy numbers (2 – 369) (Table 3.5). As 
previously discussed, the three outliers in the 19 IFA-negative, nPCR-positive results were 
excluded from the range given in Table 3.5. 
 
Table 3.5 Median copy number of P. jirovecii DNA in the positive and negative nested 
PCR (nPCR) specimens, 2005-2009, Gauteng, South Africa 
 
Median copy number of DNA in qPCR positive 
specimens (range) IFA result category 
  nPCR positive nPCR negative 
IFA positive 14 498 (57 - 704 257) 98 (7 - 369) 
IFA possibly positive 729 (134 - 2 566) 131 (60 - 202) 
IFA negative 823 (14 – 15 377) 12 (2 - 64) 
 
 
3.3.2 Sequencing of PCR products 
Figures 3.4, 3.5 and 3.6 illustrate examples of electropherograms of a basic genotype, 
resolvable mixed genotype and irresolvable mixed genotype, respectively. The maroon 
rectangles in the electropherograms identify nucleotide positions 165 and 171, 
respectively. Primary sequencing results of the nPCR products showed the presence of 
seven of the nine possible DHPS genotypes, with the wild type genotype being most 
prevalent (Table 3.6).  
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Figure 3.4 Electropherogram showing a P. jirovecii basic DHPS genotype (M2) result 
 
 
Figure 3.5 Electropherogram showing a P. jirovecii resolvable mixed DHPS genotype 
(WT + M1) result 
 
 
 
Figure 3.6 Electropherogram showing a P. jirovecii irresolvable mixed DHPS genotype 
result 
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Table 3.6 Results of primary sequencing of the P. jirovecii DHPS gene, 2005-2009, 
Gauteng, South Africa (N = 173) 
 
Genotype Number (%) 
WT (Wild type) 61 (35%) 
M1 (Mutation 1) 0 (0%) 
M2 (Mutation 2) 11 (6%) 
Single and double mutations 
M3 (Mutation 3) 12 (7%) 
WT + M1 11 (6%) 
WT + M2 35 (20%) 
M1 + M3 0 (0%) 
Resolvable mix 
M2 + M3 2 (1%) 
Irresolvable mix  41 (24%) 
 
A large proportion (24%) of the primary sequencing results showed irresolvable mixed 
genotypes (Figure 3.7), which could not be resolved by the initial sequencing. The 
P. jirovecii DHPS gene from these 41 specimens were cloned and resequenced. 
 
WT
M1
M2
M3
WT + M1
WT + M2
M1 + M3
M2 + M3
Mixed
 
Figure 3.7 Primary sequencing results of the P. jirovecii DHPS gene, 2005-2009, Gauteng, 
South Africa* 
*Key: WT = wild type, M1 = mutation 1 (mutation at position 165), M2 = mutation 2 (mutation at position 
171), M3 = mutation 3 (mutations at positions 165 and 171), Mixed = irresolvable mixed genotypes 
Results 
 50 
3.4 Resolution of mixed DHPS genotypes 
Thirteen different genotypes were identified with the secondary sequencing, with the wild 
type + M3 genotype being most prevalent (Table 3.7). Figure 3.8 highlights the 
predominant genotypes from both the primary and secondary sequencing. Fifteen percent 
(6/41) and 24% (10/41) of the secondary sequencing were basic genotypes and resolvable 
mixed genotypes respectively. 
 
Table 3.7 Secondary sequencing results of the DHPS gene in P. jirovecii isolated from 
patients with PCP, 2005-2009, Gauteng, South Africa (N = 41) 
 
Genotype Number (%) 
WT (Wild type) 2 (5%) 
M1 (Mutation 1) 0 (0%) 
M2 (Mutation 2) 1 (2%) 
Single and double mutations  
M3 (Mutation 3) 3 (7%) 
WT + M1 5 (12%) 
WT + M2 1 (2%) 
M1 + M3 1 (2%) 
Resolvable mixed genotypes 
M2 + M3 3 (7%) 
WT + M3 11 (27%) 
WT + M1 + M2 3 (7%) 
WT + M1 + M3 1 (2%) 
WT + M2 + M3 7 (17%) 
M1 + M2 + M3 2 (5%) 
Mixed genotypes 
WT + M2 + M1 + M3 1 (2%) 
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Figure 3.8 Secondary sequencing results (represented by the bar) of all irresolvable mixed 
genotypes (hatched purple) identified by primary sequencing (represented by the pie) of 
the P. jirovecii DHPS gene, 2005-2009, Gauteng, South Africa* 
*Key: WT = wild type, M1 = mutation 1 (mutation at position 165), M2 = mutation 2 (mutation at position 
171), M3 = mutation 3 (mutations at positions 165 and 171) 
 
When the results of primary and secondary sequencing were combined, the two 
predominant genotypes were wild type (36%), and the wild type + M2 genotype (21%) 
(Table 3.8 and Figure 3.9).  
 
Results 
 52 
WT  
M2
M3
WT + M1
WT + M2
WT + M3
M1 + M3
M2 + M3
WT + M1 + M2
WT + M1 + M3
WT + M2 + M3
M1 + M2 + M3
WT + M1 + M2 + M3
Table 3.8 Combined final sequencing results of the P. jirovecii DHPS gene, 2005-2009, 
Gauteng, South Africa (N = 173) 
Genotype Number (%) 
WT (Wild type) 63 (36%) 
M1 (Mutation 1) 0 (0%) 
M2 (Mutation 2) 12 (7%) 
Single and double mutations 
M3 (Mutation 3) 15 (9%) 
WT + M1 16 (9%) 
WT + M2 36 (21%) 
M1 + M3 1 (1%) 
M2 + M3 5 (3%) 
WT + M3 11 (6%) 
WT + M1 + M2 3 (2%) 
WT + M1 + M3 1 (1%) 
WT + M2 + M3 7 (4%) 
M1 + M2 + M3 2 (1%) 
Mixed genotypes 
WT + M1 + M2 + M3 1 (1%) 
 
 
Figure 3.9 Final sequencing results of the P. jirovecii DHPS gene, 2005-2009, Gauteng, 
South Africa* 
*Key: WT = wild type, M1 = mutation 1 (mutation at position 165), M2 = mutation 2 (mutation at position 
171), M3 = mutation 3 (mutations at positions 165 and 171) 
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Forty patients had a repeat specimen taken; the results for these patients are shown in 
Appendix H. The majority (53%, 21/40) of patients had negative results for both 
specimens, 25% (10/40) of patients had positive qPCR results for both specimens, 15% 
(6/40) patients had an initial negative result and a subsequent positive result and 8% (3/40) 
had an initial positive result and a subsequent negative result. Of the ten patients who had 
positive results for both specimens, the P. jirovecii DHPS genotypes were different in five 
patients. 
 
3.5 DHPS genotypes and in-hospital patient outcome 
There was no significant difference between age and DHPS genotype (p-value = 0.09; 
Student’s t-test). There was no association between in-hospital outcome and DHPS 
genotype (p-value = 0.19; Fisher’s exact test), but there was between gender and DHPS 
genotype (p-value = 0.02; Fisher’s exact test) (Table 3.9).   
 
Table 3.9 Comparison of age, gender and in-hospital patient outcome with P. jirovecii 
DHPS genotypes, 2005-2009, Gauteng, South Africa 
 Wild type Mutations p-value 
Age, median 33 36 0.09 
Gender   0.02 
   Male 23 20  
   Female 43 87  
In-hospital patient outcome   0.19 
   Died 19 44  
   Discharged 44 65  
 
When each mutant DHPS genotype was compared to the wild type genotype, only the M2 
genotype was associated (p-value = 0.02, Fisher’s exact test) with patient in-hospital 
mortality (Table 3.10). 
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Table 3.10 Comparison of each P. jirovecii DHPS genotype and in-hospital patient 
outcome, 2005-2009, Gauteng, South Africa (N = 162)* 
 
  Died Discharged p-value 
Wild type (WT) 18 40 n/a 
Mutations 42 62 0.31 
     M2 (Mutation 2) 8 3 0.02 
     M3 (Mutation 3) 8 7 0.14 
     WT + M1 (M1 = Mutation 1) 8 7 0.14 
     WT + M2 13 23 0.66 
     WT + M3 2 8 0.71 
     M1 + M3 0 1 1.00** 
     M2 + M3 1 3 1.00** 
     WT + M1 + M2 1 1 0.54** 
     WT + M1 + M3 0 1 1.00** 
     WT + M2 + M3 1 5 0.66** 
     M1 + M2 + M3 0 2 1.00** 
     WT + M1 + M2 + M3 0 1 1.00** 
*The first result of the 10 patients who had repeat specimens taken, were excluded from analysis 
**Statistical test influenced by small numbers 
 
A summary of all results of this project is illustrated in Figure 3.10. 
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Figure 3.10 Summary of results from P. jirovecii DHPS mutation study, 2005-2009, Gauteng, South Africa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The IFA test could not be completed for one specimen due to a laboratory error that occurred during processing 
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CHAPTER 4 - DISCUSSION 
 
Pneumocystis pneumonia is often diagnosed clinically and radiologically in SA, which 
explains why there are limited data sources from which prevalence can be determined. 
However, we do know that 10.5% of the South African population is HIV positive [135], 
and since PCP is known to be one of the most common opportunistic infections in 
HIV/AIDS patients, we can presume that a substantial number of PCP cases will emerge 
from these 5.24 million people. This study, carried out at CHB Hospital in Gauteng 
Province, SA, found a 67% prevalence of PCP (including possible cases of colonisation) in 
a group of patients clinically suspected of having PCP.  
 
The average age in the study population was 35 years which falls within the main age 
group affected by HIV/AIDS, namely the 15-49 year age group [135]. The majority (73%) 
of patients were female; however this is in accordance with the national higher prevalence 
of HIV in females, and the fact that there are generally more females registered at CHB 
Hospital [personal communication with Dr Michelle Wong, CHB Hospital].  
 
There was no seasonal trend observed; however, patient recruitment throughout the 
collection period was inconsistent due to variable availability of the clinician and study 
nurse. In 2008 and 2009 there was a marked increase in patient enrolment, most likely 
attributable to the appointment of a new, dedicated study nurse.  
 
4.1 Validation of the RMPC 
When comparing the RMPC to the Qiagen method (Experiment 3), one IFA-negative 
sample was found to have 14 copies of DNA following extraction by the Qiagen method. 
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As the IFA method is not as sensitive as PCR, this result was more likely to be a true 
positive rather than a contaminated specimen. A noteworthy finding made through this 
validation was that shaking the cartridges, in order to settle the magnetic beads to the 
bottom of the well, increased the DNA yield substantially. The increased starting and 
loading volumes and the choice of protocol also affected the DNA yield, highlighting the 
importance of consistency in methodology, as minor technical changes do affect results. 
Following the validation of the RMPC, the technical findings were incorporated into the 
development of a standardised method. 
  
The RMPC was comparable to the Qiagen method in terms of repeatability and showed no 
possibility of cross-contamination between specimens, as was found by another study 
[136]. Although PCR is an indirect measure of DNA concentration, the qPCR results 
showed that the RMPC does not extract as much DNA from a clinical specimen as the 
Qiagen method, especially at high DNA concentrations. This is most likely due to the 
RMPC method using magnetic bead technology to extract the DNA; the beads are limited 
and can therefore be overloaded at high DNA concentrations [74]. In addition, this method 
uses cartridges containing wells in which the DNA is passed from one to the next, and loss 
of DNA may occur during this transfer. However, when the bacterial protocol was used, 
there was no significant difference in DNA yield between the RMPC and the Qiagen 
method. For this reason, along with the other strengths of the method, namely ease of use 
and speed, the RMPC method was selected for use. Two similar studies which compared 
automated extraction methods against manual methods both found the Roche MagNA Pure 
(a higher throughput version of the RMPC which uses the same magnetic bead technology) 
comparable to the manual extraction method [136;137].  
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4.2 Diagnostic methods 
Despite the advances in molecular biology, at present resource limitations in many 
laboratories rule out PCR as an option. As a result staining methods, particularly 
immunofluorescent antigen staining, are still commonly used for the diagnosis of 
P. jirovecii [60]. In this study the IFA method identified 51% of specimens as positive. Of 
the three IFA-positive specimens that were found to be negative by qPCR, two showed 
PCR inhibition. On careful examination of the slide from the remaining specimen, it was 
evident that while there was a clear presence of fluorescence, the morphology of the 
fluorescent material was not consistent with that of P. jirovecii and therefore this was most 
likely a false positive IFA result. Non-specific staining is a limitation of IFA kits for 
P. jirovecii [69], especially if coupled with inexperienced microscopists. The IFA stain 
was shown to have the highest sensitivity but the lowest specificity when compared to 
three other staining methods [60]. However, Khan et al. [71] concluded that 
immunofluorescence should not be used solely for the diagnosis of PCP, and that PCR 
should be used when the IFA result is negative and the patient is suspected of having PCP. 
 
In this study, the qPCR assay identified 67% of specimens as positive for P. jirovecii. It 
had a good sensitivity (98%) and negative predictive value (96%) when compared to the 
IFA test as the gold standard. The lower specificity (70%) and positive predictive value 
(80%) were influenced by the large number of apparent false positive results. However, 
these are most likely to be true cases, as PCR is known to be more sensitive than IFA. As 
these specimens had an overall lower copy number of DNA, compared to the true positive 
results, they may be from patients who are colonised rather than infected with P. jirovecii 
[71]. If this is true, then these patients probably have another respiratory disease as they 
were recruited because of their clinical presentation. A study that compared a PCR assay to 
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an IFA method for P. jirovecii diagnosis, found the PCR assay had a low sensitivity (55%)  
and specificity (41.2%) [69]. However, when the discrepant results were analysed using 
clinical data and further laboratory testing the sensitivity and specificity of the PCR 
increased substantially. Following this study, the qPCR assay for P. jirovecii is being 
added to the list of routine tests offered by the PRU, NICD. 
 
A major problem when evaluating a test for PCP diagnosis is the lack of a true gold 
standard. This is due to the non-existence of a culture system for P. jirovecii. The IFA test 
was chosen as the gold standard in this project because it is the current routine diagnostic 
test for PCP, used by the laboratory. In the absence of a good gold standard, it has been 
suggested that other analytic approaches, such as composite reference standards, be used 
[138]. Such approaches draw on the strengths of a number of different methods to 
compensate for the imperfectness of the individual methods themselves. In addition, the 
use of clinical and radiological criteria may serve as a good gold standard for P. jirovecii 
diagnosis, as was used by Fujisawa et al. [139]. Consequently, it must be noted that the use 
of an imperfect gold standard in this project, negatively affected the statistical measures, 
especially the specificity, of the qPCR assay.  
 
A very important question remains unanswered with respect to using qPCR for PCP 
diagnosis: what is the appropriate cut-off value for colonisation versus infection? In order 
to determine accurate cut-offs, many criteria need to be analysed along with the Ct 
value/DNA copy number, such as patients’ clinical presentation and chest x-rays. For this 
project, only the results of two diagnostic tests (i.e. IFA and qPCR) were available for 
analysis. The results showed a good correlation between the median DNA copy number 
and IFA result i.e. low copy number for IFA-negative specimens and increasingly higher 
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copy numbers for IFA-possibly positive and IFA-positive specimens (+, ++ and +++). The 
median copy number was used instead of the mean to reduce the effect of outliers. 
However, there was a large overlap in the range of copy numbers in each category and this 
makes it difficult to determine clear cut-offs. Based on these results, proposed arbitrary 
cut-offs are less than or equal to 100 copies of DNA for colonisation, between 100 - 1 000 
copies indeterminate and greater than or equal to 1 000 copies for infection. As previously 
discussed, the IFA test is not a reliable gold standard because it does not always distinguish 
true infection from colonisation; therefore these cut-offs are highly subjective.  
 
While the majority of studies comment on the need for cut-off values, only a few provide 
possible values. Arbitrary cut-offs of 10, 30 and 50 copies/tube have been applied in 
studies [63;139-141]. Most of these reports also state the important fact that higher cut-offs 
increase specificity but decrease sensitivity of the real-time assay. It is strongly advised 
that the test result be combined with the clinical presentation of the patient before a 
diagnosis of PCP is made [69]. Linssen et al. suggested that patients be divided into three 
groups on the basis of a positive or negative laboratory test result and the presence or 
absence of compatible clinical symptoms [142]. Patients with positive test results and 
symptoms will have PCP, patients with negative test results and no symptoms will not 
have PCP and patients with positive test results and no symptoms will be carriers. If there 
are patients with PCP symptoms and negative test results, the test should be repeated and 
the patient monitored. 
 
Although the nPCR was not used as a diagnostic test in this study but rather to facilitate 
sequencing of the DHPS gene, statistical comparisons with the IFA and qPCR tests were 
performed. The nPCR had a high sensitivity (94%), but a low specificity (55%) compared 
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to the IFA, but as discussed previously, the IFA is not a good gold standard. The qPCR 
positive specimens that were nPCR negative had mostly low copy numbers, which has 
been found in a previous study [143]. The authors of this study found that when qPCR and 
nPCR were compared to microscopy, the qPCR and nPCR had the same sensitivity but the 
qPCR had a statistically better specificity compared to the nPCR. This was due to the high 
number of false positives with the nPCR. Such comparisons cannot be done in this study 
because not all specimens were processed by nPCR, only the qPCR positives. Excluding 
the costs of the thermocycler qPCR is cheaper than nPCR, four times faster, quantifies 
positive results and is less susceptible to contamination.  
 
4.3 DHPS genotypes 
The majority of specimens (64%) harboured a mutant DHPS genotype. This is unusual 
compared to most other studies carried out across the world, in which the wild type DHPS 
genotype was most predominant in nearly all samples tested [101;108;116;124;128]. Four 
studies that found higher rates of mutations (65% to 81%) were all carried out in the 
United States [37;112;114;119]. It is strongly suggested that DHPS mutations arise as a 
result of sulfa drug pressure, and as these drugs are not widely used in most developing 
countries the prevalence of DHPS mutations is low [127]. As the use of sulfa drugs 
increases, so does the prevalence of DHPS mutations in many organisms, including 
P. jirovecii [110]. In SA, sulfa drugs (particularly cotrimoxazole) have become widely 
used in recent times because of HIV-related indications, as well as general use for a wide 
variety of diseases, including cholera, some bacterial infections and urinary tract infections 
{Anonymous, 2010 148 /id}. This widespread use of sulfa drugs is the most likely reason 
for the increase of P. jirovecii DHPS mutant genotypes in our population.  
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Further to the high prevalence of mutant DHPS genotypes, we found a large proportion 
(24%, 41/173) of irresolvable mixed genotypes. This was also the case in the previous 
study done by our group in SA, in which 36% (31/85) of mutant genotypes were of the 
irresolvable category [129]. This highlights the need to resolve these genotypes in order to 
accurately identify the predominant DHPS genotypes circulating in our population. In 
contrast, the majority of other studies found mostly wild type and basic genotypes; a few 
mixed genotypes were found, and these were mostly resolvable mixed genotypes 
[109;116;117].  
 
RFLP analysis and primary sequencing are commonly used to determine DHPS genotypes. 
The limitation of these methods is that any irresolvable mixed genotypes cannot be 
discerned from the results. To clone and resequence allows for unambiguous results to be 
obtained for all specimens. The number of colonies screened and sequenced is very 
important and, if too few, may bias the results. Other groups that used the cloning method 
to determine DHPS genotypes screened either five colonies [14;126]; three to eight 
colonies [116] or ten colonies [120] for each specimen. We chose to screen ten colonies for 
each specimen to increase sensitivity. However, even using ten colonies, some of our 
secondary sequencing results showed basic and resolvable mixed genotypes only. As these 
specimens clearly contained P. jirovecii with mixed genotypes from the primary 
sequencing results, this could mean that the number of colonies screened was too few to 
identify the genotypes present in low volumes. This could be seen as a limitation in this 
project.  
 
The most common DHPS mutant genotypes found in this sample of patients were the wild 
type + M2 (21%), wild type + M1 (9%), M3 (9%) and M2 (7%) genotypes. This was 
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consistent with the previous study we did in SA, in 2006 to 2007, where the most common 
genotypes were M3 (18%), wild type + M1 (18%) and wild type + M2 (12%) genotypes 
[129]. Interestingly, in this project there were no M1 genotypes, which we found 
previously. Overall, when comparing the results of P. jirovecii DHPS studies carried out in 
different countries, there does seem to be more basic genotypes present than mixed 
genotypes. In the USA in particular there appears to be a predominantly large number of 
M3 genotypes. Distribution trends of the P. jirovecii DHPS genotypes have not been well 
documented.  
 
Only mutations at nucleotide positions 165 and 171 in codons 55 and 57 respectively, were 
analysed in this project, as these mutations lead to specific amino acids changes that have 
been linked to sulfa drug resistance [37]. In the E. coli DHPS enzyme, threonine at codon 
62 is homologous to threonine at codon 55 in P. jirovecii. When a mutation results in an 
amino acid change from threonine to alanine in this position, one of the two hydrogen 
bonds between the DHPS enzyme and the substrate pteridine is lost [106]. The adjacent 
amino acid in both P. jirovecii and E. coli is arginine at codons 56 and 63, respectively. 
This amino acid is also involved in the binding of pteridine; therefore amino acid changes 
on either side of it may affect its positioning and thus affect binding to the substrate. 
Another group in SA looked for any mutations in codons 55 and 57 of the P. jirovecii 
DHPS gene [124]. They found 13% (4/30) of specimens with mutations, one wild type + 
M1 genotype and three with mutations at position/s 166 and/or 172. 
 
Repeat specimens were collected from 40 patients; mainly due to the clinician strongly 
suspecting PCP despite the initial negative laboratory result. Two patients were readmitted 
but the other 38 had two specimens collected on their initial admission. The interval 
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between sample collections from the latter group of patients ranged from the same day to 
29 days. Repeat specimens collected from the same patients showed that some patients had 
one positive and one negative result in their respective specimens; this may be due to 
variable specimen quality. It was also found that some patients had different DHPS 
genotypes in the two specimens. As stated by Miller et al. [35], if PCP is due to a 
reactivation of a latent infection, the genotypes should remain the same. However, it is 
possible that the organism is mutating in the host under the influence of the sulfa drugs 
[14]. Alternatively, the patients may have been re-infected with a new strain, but this 
seems unlikely as most repeat specimens were taken within one to two days. 
 
4.4 DHPS genotypes and in-hospital patient outcome 
The results from this project show that there appears to be no significant association 
between DHPS genotype and adverse patient outcome. Published data provide conflicting 
evidence on this topic. The data for patient outcome were based on the in-hospital data; 
further follow-up could alter the data as patients may have died after discharge. On the 
other hand, the in-hospital deaths could have been due to other causes, and not necessarily 
the PCP infection. If it is concluded that the outcome and mutations are not linked, what 
would be the value of investigating the mutations? For the mutations to have significance 
they must be associated with clinical impact. 
 
When individual DHPS genotypes were compared with the wild type genotype, the M2 
genotype was associated with a worse patient outcome. However, as the numbers in many 
of the DHPS genotype groups were small, these results may not be indicative of a true 
association. If such a result were confirmed with a larger set of data in future, the need to 
determine the DHPS genotype would be justified. 
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The problem of PCP drug alternatives may arise, if it is found conclusively that DHPS 
mutations are associated with sulfa drug resistance. Dapsone is the second choice 
prophylactic drug for PCP but it offers little and no protection against toxoplasmosis and 
bacterial infections, respectively, unlike cotrimoxazole which is active against both 
{Anonymous, 2010 148 /id}. It has not been irrefutably determined that patients with 
P. jirovecii with DHPS mutations fail treatment or have a worse outcome. Some studies 
have shown that treatment with sulfa drugs was unsuccessful in these patients [110], while 
others have shown that patient outcome is not affected by the presence of P. jirovecii 
DHPS mutations [36].  
 
4.5 Future studies 
It is important to continue monitoring the P. jirovecii DHPS mutations in those infected 
with PCP in SA, especially as sulfa drug usage increases. In future, it would be beneficial 
to investigate the DHPS mutations in HIV-negative patients with PCP as well, especially 
because of the higher mortality and worse presentation of the disease in these patients [54]. 
 
Further to this project, the larger study aims to investigate the associations between the 
P. jirovecii DHPS mutations and PCP prophylaxis, treatment failure, and 3-month patient 
outcome. It will also explore risk factors for PCP, the effect of exposure to HAART and 
PCP prophylaxis, mixed infections and PCP prophylactic drug usage, dosage and 
adherence thereof. Correlation between clinical and radiological findings and laboratory 
diagnosis will be analysed. These data will be paramount to establishing information 
regarding PCP infection in HIV-positive patients in SA.  
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CHAPTER 5: CONCLUSIONS 
 
With respect to DNA extraction methodology, from the experiments carried out for the 
RMPC validation, it can be concluded that DNA extraction with the RMPC instrument is 
useful in a high-throughput diagnostic laboratory as the process is automated and saves a 
great amount of time compared to the Qiagen manual extraction method. Quantitative PCR 
is a good diagnostic tool for P. jirovecii especially if an accurate cut-off value to 
differentiate between colonisation and infection is determined. An arbitrary cut-off of 100 
– 1 000 copies of DNA has been proposed but this may be inaccurate.  
 
Pneumocystis jirovecii pneumonia is one of the most common opportunistic infections in 
HIV/AIDS patients. In SA the burden of this disease remains largely unknown, mainly 
because the disease is frequently diagnosed and treated empirically. In this study 
population, we found a 67% positivity rate in specimens from patients suspected of PCP. 
The need to continue efforts to estimate the true burden of PCP in our country must be 
emphasised. 
 
The majority of specimens collected in this study contained P. jirovecii mutant DHPS 
genotypes. This provides further evidence that these mutations do exist in developing 
countries and are most likely increasing because of the widespread use of sulfa drugs. 
There are conflicting data regarding the importance of these mutations, and the results of 
this project support the argument that DHPS mutations do not appear to have an effect on 
patient outcome. However, this does not diminish the need to continually examine the 
impact, if any, of these mutations. The possibility that they do cause clinical resistance to 
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sulfa drugs will have an immense impact on health care and therefore warrants further 
investigation.  
 
Appendices 
 68 
Appendix A – Informed consent form 
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Appendix B – Clinician case report form 
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Appendix C – Reagent recipes 
 
To prepare DTT solutions 
• 65 mM stock solution (50 ml) Add 0.5 g of DTT to 50 ml of distilled water 
• 6.5 mM DTT working solution Add 1 part stock solution to 9 parts of  
phosphate buffered saline pH 7.2 (DMP) 
 
To prepare qPCR standards 
• Prepare fish sperm DNA working solution by adding 5 µl fish sperm DNA (Roche 
Diagnostics) to 4495 µl water into a 15 ml tube and vortex well. 
• Aliquot 90 µl of the fish sperm DNA working solution into a 1.5 ml tube labelled 
‘10-5’, and 360 µl into tubes labelled ‘10-6’, ‘10-7’, ‘10-8’, ‘10-9’ and ‘10-10’ tubes. 
• Add 10 µl of standard 10-4 (donated by the Swedish Institute for Infectious 
Diseases) to the 90 µl of fish sperm DNA working solution in the standard 10-5 
tube, pulse vortex 3 times and centrifuge (1 minute at maximum speed). 
• Add 40 µl of standard 10-5 to 360 µl of fish sperm DNA working solution in the 
standard 10-6 tube, vortex and centrifuge (as above). 
• Continue making 1 in 10 dilutions and then dispense into 17 µl aliquots. 
• Standards should not be refrozen; therefore these aliquots are single use, allowing 
for three replications per plate. 
 
To prepare TAE buffer solutions 
• 10x TAE stock solution  Add 48.4 g Tris (Sigma Aldrich, Steinheim,  
Germany) and 7.44 g of EDTA (Merck 
Chemicals, Gauteng, South Africa) to 
11.42 ml of acetic acid. Make up to 1 litre 
with distilled water. 
 
• 1x TAE buffer    Add 1 part stock solution to 9 parts of  
distilled water. 
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To prepare X-gal 
• 40 mg/ml X-gal solution  Add 1.25 ml of DMSO (Merck Chemicals) to   
50 mg of X-gal, vortex and store at 20°C. 
 
To prepare ampicillin   
• 50 mg/ml ampicillin solution  Add 1 ml of PBS pH 7.2 (DMP) to 50 mg of  
ampicillin (Sigma Aldrich), vortex and store 
at 4°C. 
 
To prepare LB, with 50 µg/ml ampicillin 
• Luria Broth (1 L)   Combine 10 g Bactotryptone (Duchefa,  
Haarlem, The Netherlands), 10 g NaCl 
(Merck Chemicals) and 5 g of yeast extract 
(Oxoid Ltd, Hampshire, England). Make up to 
1 litre with water. Autoclave, cool, add 1 ml 
of 50 mg/ml ampicillin and refrigerate.  
 
• Luria broth plates (~25 plates) Add 11.25 g of Bactoagar (Becton, Dickinson  
and Company, Sparks MD 21152, USA) to 
750 ml of LB. Mix well, autoclave, cool 
slightly and add 750 µl of 50 mg/ml 
ampicillin. Pour aseptically into Petri dishes, 
allow to cool and refrigerate. 
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Appendix D – Extraction method with the Qiagen DNA Mini Kit  
 
1. Aliquot 50 µl of washed sample into a 1,5 ml labelled tube. 
 
2. Add 150 µl of ATL buffer. 
 
3. Add 20 µl Proteinase K (Roche Diagnostics), mix by vortexing, and incubate at 56°C 
for 2 hours. Vortex occasionally during incubation to disperse the sample. 
 
4. Briefly centrifuge the tubes to remove drops from the inside of the lid. Add 200 µl 
Buffer AL to the sample, mix by pulse-vortexing for 15 seconds, and incubate at 70°C 
for 10 minutes.  
 
5. Briefly centrifuge the tube. Add 200 µl ethanol (96-100%) to the sample, mix by pulse-
vortexing for 15 seconds and centrifuge briefly again. 
 
6. Carefully apply the mixture (including the precipitate, ±650 µl) to QIAamp spin 
column (in a 2 ml collection tube) without wetting the rim. Close the cap, and 
centrifuge at 6000 x g (8000 rpm) for 1 minute. Place the QIAamp spin column in a 
clean 2 ml collection tube (provided), and discard the tube containing the filtrate. 
 
7. Carefully open the QIAamp spin column and add 500 µl Buffer AW1 without wetting 
the rim. Close the cap, and centrifuge at 6000 x g (8000 rpm) for 1 minute. Place the 
QIAamp spin column in a clean 2 ml collection tube (provided), and discard the 
collection tube containing the filtrate. 
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8. Carefully open the QIAamp spin column and add 500 µl Buffer AW2 without wetting 
the rim. Close the cap and centrifuge at full speed (20,000 x g; 14,000 rpm) for 4 
minutes. 
 
9. Place the QIAamp spin column in a new 2 ml collection tube (not provided, use 1.5 ml 
tube with lid removed) and discard the collection tube containing the filtrate. 
Centrifuge at full speed for 1 minute. 
 
10. Place the QIAamp spin column in a clean labelled 1.5 ml microcentrifuge tube (not 
provided), and discard the collection tube containing the filtrate. Carefully open the 
QIAamp spin column and add 100 µl Buffer AE. Incubate at room temperature for 5 
minutes and then centrifuge at 6000 x g (8000 rpm) for 5 minutes. 
 
11. Discard the column and store at -70°C. The final volume is 100 µl. 
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Appendix E – Ethics clearance certificate  
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Appendix F: Results of the RMPC validation experiments 
 
 
Experiment 1: Cross-contamination in the RMPC  
 
Specimen qPCR copy number 
Positive A 11,600,000 
Positive B 5,000,000 
Positive C 7,700,000 
Positive D 1,100,000 
Negative A, B, C and D 0 
 
 
 
Experiment 2: Comparison of the RMPC versus the manual Qiagen method 
 
Specimen 
number IFA Result 
RMPC 
qPCR copy number 
Qiagen 
qPCR copy number 
002 Negative 0 0 
003 Negative 0 0 
004 Negative 0 0 
005  Negative 0 0 
006 Negative 0 0 
007 Negative 0 0 
008 Negative 0 0 
009 Negative 0 0 
010 Negative 0 14 
011 Negative 0 0 
012 Negative 0 0 
013 Negative 0 0 
014 + 868,108 1,800,000 
015 + 467 32,098 
016 +++ 19,347 9,330,000 
017 +++ 681,156 1,260,000 
018 ++ 32,344 24,902 
019 + 32 122 
020 +++ 984,027 5,160,000 
021 +++ 702,019 3,050,000 
022 +++ 119 803 
023 +++ 1,220 98,057 
024 ++ 240 1,032 
025 ++ 4,483 4,682 
 
Using a Wilcoxon matched-pairs signed-rank test, p-value = 0.01 (significant). 
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Experiment 3: Technical optimisation of the use of the RMPC reagents 
 
  Exp.2 Exp.3 
  Cartridges not shaken Cartridges shaken 
Specimen 
number qPCR, copy number 
014 272,926 603,090 
015 214 2,087 
016 15,460 319,251 
017 325,562 876,149 
018 14,087 143,476 
019 0 1,497 
020 419,126 1,070,000 
021 253,133 857,057 
022 20 170 
023 642 9,776 
024 46 1,877 
025 2,515 2,525 
 
Using a Wilcoxon matched-pairs signed-rank test, p-value < 0.05 (significant). 
 
 
Experiment 4: Repeat of the comparison of the RMPC versus the manual Qiagen method 
experiment 
 
  RMPC (Exp.3) Qiagen (Exp.2) 
  Cartridges shaken - 
Specimen 
number qPCR, copy number 
014 1,160,000 1,320,000 
015 1,606 2,288 
016 395,457 6,650,000 
017 1,320,000 1,030,000 
018 194,287 12,654 
019 884 0 
020 738,078 3,650,000 
021 973,967 2,580,000 
022 128 819 
023 6,054 53,619 
024 1,085 693 
025 1,618 3,846 
 
Using a Wilcoxon matched-pairs signed-rank test, p-value = 0.20 (not significant). 
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Experiment 5: Robustness 
 
Starting volume 50µl 20µl 50µl 20µl 
Loading volume* 200µl 100µl 
Copy number 115 71 53 8 
 
All negatives were undetermined 
*Setting on robot could not be changed and was set at 200µl 
 
 
Experiment 6: Repeatability 
 
    
RMPC Qiagen 
Specimen 
number 
  
Copy 
number 
Average 
copy 
number 
Copy  
number 
Average 
copy 
number 
Low 1 12 0 
Low 2 35 24 035 
Low 3 0 
23 
68 
46 
Med 1 269 341 
Med 2 704 192 036 
Med 3 509 
494 
371 
301 
High 1 99,930 231,798 
High 2 70,367 191,118 037 
High 3 94,350 
88,216 
184,039 
202,318 
 
Using a paired t test, p-value = 0.09 (not significant). 
 
Experiment 7: Varying instrument protocols 
 
  
RMPC-Bacterial 
protocol 
RMPC-Total NA 
protocol Qiagen 
Specimen 
number 
 
Copy 
number 
Average 
copy 
number 
Copy 
number 
Average 
copy 
number 
Copy 
number 
Average 
copy 
number 
Low 1 0 0 0 
Low 2 0 0 0 038 
Low 3 0 
N/A 
0 
N/A 
0 
N/A 
Med 1 2,359 1,242 4,082 
Med 2 2,195 2,272 2,942 039 
Med 3 2,581 
2,378 
1,290 
1,601 
2,321 
3,115 
High 1 443,354 265,262 930,288 
High 2 397,383 275,765 806,058 040 
High 3 421,937 
420,891 
392,052 
311,026 
399,024 
711,790 
 
Using a Dunn’s multiple comparison test, there is only a significant difference between the 
RMPC - Total NA protocol and the Qiagen method 
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Appendix G: PCR protocol to detect inhibition in a clinical sample 
This assay amplifies the human ribonuclease P (RNase P) gene. 
 
1. Prepare a 25 µl reaction mixture consisting of  
• 12.5 µl of 2x TaqMan gene expression master mix (Applied Biosystems),  
• 1 µl of primer RNaseP-F (5’-CCA AGT GTG AGG GCT GAA AAG-3’) mix at 10 µM,  
• 1 µl of primer RNaseP-R (5’-TGT TGT GGC TGA ACT ATA AAA GG-3’) mix at 10 µM,  
• 0.5 µl of RNaseP-Probe [5’VIC-CC CCA GTC TCT GTC AGC ACT CCC TTC-3’NFQ (MGB 
Probe)] at 5 µM,  
• 7.5 µl of water and  
• 2.5 µl of DNA.  
Prepare for three extra samples, two for a positive and negative control and one for 
pipetting errors. Add all regents except the DNA, vortex and centrifuge briefly.  
 
2. The master mix was pipetted into 96 well MicroAmp plates (Applied Biosystems). 
Add the DNA templates accordingly. Plates were covered with an adhesive optic 
film or caps (Applied Biosystems) and centrifuged at 3000 rpm for 10 seconds.  
 
3. Load the plate into the real-time PCR instrument; select an absolute quantification 
(standard curve) assay with the Applied Biosystems SDS v 1.3.1 programme. 
Select detector VIC and apply to the appropriate wells.  
 
4. The PCR assay parameters are as follows: 2 minutes at 50°C, 10 minutes at 95°C, 
followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.  
 
5. A positive result (Ct value >40) indicates that there is no inhibitory substances in 
the sample, while a negative result (Ct value <40) indicates the presence of inhibitory 
substances in the sample which is likely to inhibit other PCR assays. 
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Appendix H: Results of the 40 repeat specimens taken 
 
Patient 
number 
Date of specimen 
collection 1 and 2 
respectively 
IFA result 
qPCR 
copy 
number 
Nested PCR 
result 
DHPS 
genotype 
1 14 March 2005 Negative 0   
 31 March 2005 Negative 0   
11 18 May 2005 Negative 33 825 Positive WT 
 20 May 2005 Positive 156 Positive WT + M2 
21 02 August 2005 Negative 12 270 Positive WT + M2 + M3 
 04 August 2005 Positive 192 794 Positive WT + M3 
59 27 October 2006 Negative 22 Negative  
 03 November 2006 Positive 93 Negative  
60 01 November 2006 Possible 2 566 Positive M2 
 02 November 2006 Positive 388 Positive WT + M2 
77 24 January 2007 Negative 0   
 25 January 2007 Negative 0   
81 19 February 2007 Negative 0   
 20 February 2007 Positive 0   
82 19 February 2007 Negative 0   
 21 February 2007 Negative 0   
94 17 May 2007 Negative 0   
 18 May 2007 Negative 0   
99 04 July 2007 Negative 0   
 05 July 2007 Positive 467 Positive WT 
100 05 July 2007 Negative 29 Negative  
 11 July 2007 Positive 453 Positive WT 
103 18 July 2007 Negative 0   
 20 July 2007 Negative 0   
108 25 September 2007 Negative 0   
 25 September 2007 Negative 0   
109 26 September 2007 Possible 0   
 27 September 2007 Negative 3 Negative  
118 21 November 2007 Negative 0   
 22 November 2007 Negative 0   
120 29 November 2007 Positive 0   
 29 November 2007 Negative 0   
123 04 January 2008 Negative 0   
 08 January 2008 Negative 0   
128 08 February 2008 Negative 0   
 12 February 2008 Negative 0   
136 21 May 2008 Negative 0   
 23 May 2008 Negative 0   
138 27 May 2008 No result* 622 Positive WT + M1 + M2 
 30 May 2008 Positive 7 Negative  
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142 09 July 2008 Negative 0   
 10 July 2008 Negative 0   
148 25 July 2008 Negative 2 Not done**  
 28 July 2008 Positive 62 727 Positive WT 
151 26 August 2008 Negative 0   
 27 August 2008 Negative 0   
157 30 August 2008 Negative 18 Negative  
 02 September 2008 Negative 0   
162 11 September 2008 Negative 352 Positive WT + M1 
 15 September 2008 Negative 0   
167 22 September 2008 Possible 585 Positive WT 
 23 September 2008 Negative 475 Positive WT 
176 07 October 2008 Negative 20 Negative  
 09 October 2008 Negative 638 Positive M3 
196 12 November 2008 Negative 0   
 14 November 2008 Negative 0   
200 19 November 2008 Possible 873 Positive M2 + M3 
 21 November 2008 Negative 45 Positive M3 
201 24 November 2008 Negative 5 Negative  
 26 November 2008 Negative 0   
228 20 February 2009 Possible 202 Negative  
 22 February 2009 Possible 1 085 Positive WT + M2 
244 03 April 2009 Negative 826 Positive WT + M1 
 06 April 2009 Possible 939 Positive WT + M1 
254 13 May 2009 Possible 401 Positive WT 
 15 May 2009 Negative 1 705 Positive WT + M2 
258 18 May 2009 Possible 396 Positive WT 
 20 May 2009 Positive 1 714 Positive WT 
259 21 May 2009 Negative 4 Negative  
 22 May 2009 Negative 0   
267 26 June 2009 Possible 60 Negative  
 29 June 2009 Positive 6 529 Positive WT + M2 
* No result due to error while processing 
** Not done due to very low copy number 
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